Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets

Marta Reina-Couto1,2,3, Patrícia Pereira-Terra1, Janete Queihas-Santos1, Carolina Silva-Pereira1,2, António Albino-Teixeira1,2 and Teresa Sousa1,2*

1 Departamento de Biomedicina – Unidade de Farmacologia e Terapêutica, Faculdade de Medicina, Universidade do Porto, Porto, Portugal, 2 Centro de Investigação Farmacológica e Inovação Medicamentosa, Universidade do Porto (MedInUP), Porto, Portugal, 3 Departamento de Medicina Intensiva, Centro Hospitalar e Universitário São João, Porto, Portugal

Inflammation has been recognized as a major pathophysiological contributor to the entire spectrum of human heart failure (HF), including HF with reduced ejection fraction, HF with preserved ejection fraction, acute HF and cardiogenic shock. Nevertheless, the results of several trials attempting anti-inflammatory strategies in HF patients have not been consistent or motivating and the clinical implementation of anti-inflammatory treatments for HF still requires larger and longer trials, as well as novel and/or more specific drugs. The present work reviews the different inflammatory mechanisms contributing to each type of HF, the major inflammatory mediators involved, namely tumor necrosis factor alpha, the interleukins 1, 6, 8, 10, 18, and 33, C-reactive protein and the enzymes myeloperoxidase and inducible nitric oxide synthase, and their effects on heart function. Furthermore, several trials targeting these mediators or involving other anti-inflammatory treatments in human HF are also described and analyzed. Future therapeutic advances will likely involve tailored anti-inflammatory treatments according to the patient’s inflammatory profile, as well as the development of resolution pharmacology aimed at stimulating resolution of inflammation pathways in HF.

Keywords: inflammation, chronic heart failure (CHF), acute heart failure (AHF), cardiogenic shock (CS), inflammatory mediators, clinical trials, anti-inflammatory strategies

INTRODUCTION

Heart failure (HF) is a complex clinical syndrome caused by structural and/or functional cardiac abnormalities which result in the impairment of ventricular filling and/or ejection (Ponikowski et al., 2016). Although hemodynamic and neurohormonal counterregulatory responses are activated in order to maintain adequate tissue perfusion, their perpetuation contributes to structural and functional damage at medium and long term (Gullestad et al., 2012; Kemp and Conte, 2012; Braunwald, 2013). Chronic HF (CHF) is currently divided in three categories based on left ventricular ejection fraction (LVEF), namely reduced (HFrEF), preserved (HFpEF) or mid-range (HFmrEF) (Ponikowski et al., 2016). This last category (HFmrEF) (Castillo et al., 2020), recently individualized in European guidelines, represents an intermediate range of LVEF that has been less rigorously studied, with clinical characteristics that resemble those of the HFpEF group (Hsu et al., 2017) but with a higher prevalence of coronary artery disease, and so a similar response to the treatment of HFrEF patients (Tomasoni et al., 2019).

Despite therapeutic advances, CHF inexorably progresses with acute episodes, requiring recurrently urgent hospitalization and medical support (Ramani et al., 2010;
Ponikowski et al., 2016). Although acute heart failure (AHF) frequently refers to this acute decompensation of CHF, it may also correspond to the new-onset form (“de novo HF”) caused by direct ischemic, infectious/inflammatory or toxic insults to the myocardium, or indirectly by mechanical development of acute valve insufficiency or cardiac tamponade (Spodick, 2003; Ponikowski et al., 2016). Cardiogenic shock (CS), the severest form of these AHF syndromes, evolve as a continuum from those underlying precipitants until the subsequent state of low cardiac output, organ failure and death (Shpektor, 2010; Mebazaa et al., 2016; van Diepen et al., 2017; Chioncel et al., 2020). Therefore, there is an urgent need to explore new pathophysiological pathways and therapeutic strategies for HF (Yndestad et al., 2006; Heymans et al., 2009; Desai and Stevenson, 2012).

Inflammation is accepted as an important pathophysiological factor in both AHF and CHF, predicting poor prognosis independently of LVEF (Murphy et al., 2020), although it appears to contribute in different ways to each type of HF (Castillo et al., 2020; Murphy et al., 2020; Srivastava et al., 2020).

In HFrEF, where a more evident association with inflammatory markers is reported, underlying comorbidities, such as obesity, arterial hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease and also aging, trigger a systemic inflammatory state which cause microvascular endothelial cell inflammation associated with increased reactive oxygen species (ROS) production and decreased nitric oxide (NO) bioavailability (Paulus and Tschope, 2013). Chronic inflammation also favors the infiltration of monocytes into the myocardium and further differentiation into proinflammatory macrophages (M1) (Glezeva and Baugh, 2014). These events promote adverse left ventricle remodeling and relaxation impairment (Glezeva and Baugh, 2014).

In HfPEF, myocardial injury is the main trigger for the inflammatory responses mediated by the innate and adaptive immune systems (Van Linthout and Tschope, 2017; Adamo et al., 2020). These are characterized by an initial increase in proinflammatory cytokines and chemokines, along with the infiltration of neutrophils and monocytes into the injured myocardium (Adamo et al., 2020). Subsequently, in the resolution and repair phase (also termed “proliferative”), there is the phagocytosis of apoptotic and necrotic cells, the influx of adaptive immune cells (T-and B-cells), the activation of collagen-synthesizing myofibroblasts and the production of anti-inflammatory and proresolving molecules (e.g., transforming growth factor beta, lipoxins, IL-10) (Adamo et al., 2020). The maturation phase is marked by the apoptosis of reparative cells and scar maturation (Adamo et al., 2020). The maintenance of a chronic inflammatory status may result from sustained myocardial injury and continuous activation of proinflammatory cascades (Reina-Couto et al., 2016; Adamo et al., 2020). Importantly, activation of classic neurohormonal systems, such as the sympathetic nervous system and the renin-angiotensin-aldosterone system and hemodynamic overload can also trigger sustained myocardial inflammatory responses – termed as para-inflammation – even in the absence of tissue injury (Adamo et al., 2020). The persistence of inflammation may also be caused by a failure in the resolution of inflammation mechanisms (Reina-Couto et al., 2016). Of note, we and others have observed that CHF is associated with impaired resolution of inflammation, namely decreased plasma and urinary lipoxins in CHF patients with severe New York Heart Association (NYHA) functional classes compared to CHF patients with mild-to-moderate NYHA classes, and significantly lower plasma concentration of resolvin D1 in patients with CHF compared to healthy age-matched controls (Reina-Couto et al., 2014; Chiruchi et al., 2019). However, so far, targeting of resolution of inflammation pathways has only been attempted in experimental HF models (Reina-Couto et al., 2016; Kain et al., 2017; Halade et al., 2018).

In AHF, the inflammatory response may arise from antigenic stimulation during infection (e.g., viral myocarditis) or as a result of hemodynamic stress (Chen et al., 2008; Virzi et al., 2018). Systemic congestion and/or peripheral hypoperfusion cause neurohormonal activation, inflammation and oxidative stress which damage endothelial glycocalix and consequently impair endothelial function and fluid homeostasis (Harjola et al., 2017). Inflammatory activation also promotes a prothrombotic and proapoptotic environment (Mentz and O’Connor, 2016). Noteworthy, neurohormonal and inflammatory activation seem to persist beyond the acute event and may contribute to the high rehospitalization rates of this syndrome (Cotter et al., 2008; Reina-Couto et al., 2020). In CS, low cardiac output leads to systemic hypoperfusion caused by or followed by a systemic inflammatory response syndrome and end-organ injury that, if not promptly treated or supported, leads to death (Shpektor, 2010; van Diepen et al., 2017; Chioncel et al., 2020; Cuinet et al., 2020). Very early after CS onset, an inflammatory environment seen in 40% of the CS patients can contribute to the CS hallmark vasodilation (Kohsaka et al., 2005), with concentrations of various interleukins being associated with mortality (Prondzinsky et al., 2012). This marked inflammatory activation may be due to direct myocardial necrosis and tissue ischemia, inducing the release of damage-associated molecular patterns (DAMPs), mostly recognized by Toll-like receptor 4, highly expressed in the heart, that contributes to myocardial inflammation that occurs in HF (Yang et al., 2016). Also indirect but early secondary hypoperfusion leading to intestinal ischemia may promote the translocation of bacteria and pathogen-associated molecular patterns (PAMPs) (Shpektor, 2018; Cuinet et al., 2020) and, alongside with the release of inflammatory mediators by the spleen or adipose tissue and the para-inflammation generated by the comorbidities and endothelial dysfunction, contribute to cardiac deterioration. The intensity of this inflammatory response in CS patients is associated with CS severity (Geppert et al., 2006).

**MAJOR INFLAMMATORY MEDIATORS IN HEART FAILURE**

**Tumor Necrosis Factor Alpha**

Tumor necrosis factor alpha (TNF-α) is the most studied proinflammatory cytokine in HF (Hanna and Frangogiannis, 2020). In the heart, it can be produced by different types of
cells such as activated macrophages, cardiomyocytes, vascular cells and mast cells (Urschel and Cicha, 2015; Hanna and Frangogiannis, 2020). TNF-α exists in membrane-bound or cytosolic forms and exerts its actions by binding to cell membrane TNFR1 or TNFR2 receptors (Urschel and Cicha, 2015; Bartekova et al., 2018). TNF-α has been shown to mediate several adverse effects on heart function and structure, namely negative inotropic actions due to the disruption of calcium homeostasis, upregulation of other inflammatory molecules, including induction of inducible NO synthase, enhancement of oxidative stress and consequent mitochondrial DNA damage, promotion of apoptosis and extracellular matrix degradation and increase of microvascular endothelial permeability and activation, enhancing endothelial-leukocyte interactions (Mattila et al., 1992; Yokoyama et al., 1993; Li et al., 2000; Sanders et al., 2001; Sivasubramanian et al., 2001; Suematsu et al., 2003; Haudek et al., 2007; Hamid et al., 2009; Urschel and Cicha, 2015).

Increased TNF-α concentrations have been detected in patients with HFrEF, HFpEF, patients with AHF and CS (Levine et al., 1990; Tentolouris et al., 2004; Debrunner et al., 2008; Putko et al., 2014; Pugliese et al., 2020). Despite large evidence of the protective effects of TNF-α inhibition or deletion in experimental models of HF (Berry et al., 2004; Moe et al., 2004; Sun et al., 2007; Jobe et al., 2009), studies in HF patients have been disappointing (Chung et al., 2003; Mann et al., 2004). It has been suggested that TNF-α may exert not only deleterious, but also protective effects, which may be compromised under high intensity TNF-α blockade (Hanna and Frangogiannis, 2020; Murphy et al., 2020). Of note, in experimental cardiac ischemia-reperfusion injury, low doses of TNF-α were shown to be cardioprotective, while higher doses had deleterious cardiac effects (Rathi et al., 2002; Saini et al., 2005). Dose-dependent effects of TNF-α may difficult patient treatment since an optimal amount of this cytokine may be required to counteract excessive remodeling and preserve cardiac function (Hanna and Frangogiannis, 2020).

**Interleukin 1**

Interleukin 1 (IL-1) seems to be a major mediator of inflammation in heart diseases (Szekely and Arbel, 2018; Hanna and Frangogiannis, 2020). Among the 11 ligands of the IL-1 family, the best known members acting on the cardiovascular system are IL-1α, IL-1β, IL-18, and IL-33 (Hanna and Frangogiannis, 2020). Binding of IL-1α or IL-1β to the IL-1 type 1 receptor (IL-1R1) initiates inflammatory responses, while the IL-1 receptor type 2 (IL-1R2) functions as a decoy receptor and does not initiate signal transduction. The IL-1 receptor type 3 (IL-1R3) acts as a co-receptor for IL-1R1, being responsible for signaling after the binding of IL-1α or IL-1β to IL-1R1 (Kaneko et al., 2019). The generation of the active form of IL-1β from its precursor protein is primarily dependent on the enzymatic activity of caspase-1, which in turn is activated by the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome, a macromolecular structure containing the intracellular sensing protein NLRP3 that responds to danger-associated signals (Frangogiannis, 2015; Abbate et al., 2020). The activation of the NLRP3 inflammasome in cardiac fibroblasts and cardiomyocytes is induced by myocardial injury and may contribute to the post-infarction inflammatory process that aggravates cardiac injury (Frangogiannis, 2015; Segiet et al., 2019a).

In HF, IL-1 can be produced by immune cells, cardiomyocytes, vascular cells and fibroblasts (Hanna and Frangogiannis, 2020). IL-1 contributes to cardiac dysfunction and remodeling by reducing beta-adrenergic responsiveness of L-type calcium channels and the expression of genes involved in the regulation of calcium homeostasis, by stimulating apoptosis in cardiomyocytes, by inducing the activation of leukocytes and endothelial cells, thus promoting their interaction and increasing the recruitment of inflammatory cells to the myocardium, by favoring fibrosis and by promoting arterial stiffness and microvascular inflammation (Szekely and Arbel, 2018; Hanna and Frangogiannis, 2020). IL-1β also decreases energy production and myocardial contractility by directly damaging mitochondria (Zell et al., 1997; Szekely and Arbel, 2018).

**Interleukin 6**

The proinflammatory cytokine interleukin 6 (IL-6) is an important player in the acute phase response of inflammation, being a stimulus for C-reactive protein production by the liver, but also appears to contribute to the transition from acute to chronic inflammation by favoring the change from neutrophil to monocyte recruitment (Gabay, 2006; Huynh et al., 2015; Hanna and Frangogiannis, 2020). IL-6 is produced by several cell types like macrophages, T-lymphocytes, endothelial cells, cardiomyocytes and fibroblasts (Mihara et al., 2012; Hanna and Frangogiannis, 2020). Although both proinflammatory and anti-inflammatory effects have been described for this cytokine, its effects in HF appear to be mostly proinflammatory (Bartekova et al., 2018; Hanna and Frangogiannis, 2020).

IL-6 signaling classically involves cytokine binding to the cell surface IL-6 receptor and further association of the cytokine-receptor complex with gp130, dimerization and signaling initiation (Hanna and Frangogiannis, 2020). However, IL-6 receptor can be cleaved by proteases, originating a soluble form that can bind IL-6 and initiate signaling in cells that do not express this receptor, thus increasing the complexity of IL-6 cellular effects (Hanna and Frangogiannis, 2020). Regarding the heart, IL-6 has been shown to exert negative inotropic effects and to promote hypertrophy and fibrosis, contributing to increased myocardial stiffness (Hanna and Frangogiannis, 2020). The impairment of myocardial contractility appears to be related with the upregulation of myocardial NO synthase and downregulation of the sarcoplasmic reticulum Ca²⁺ ATPase (SERCA2) (Finkel et al., 1992; Villegas et al., 2000). IL-6 has also a negative impact on renal function since it activates the epithelial sodium channel (ENaC) in the distal tubule, impairing natriuresis (Li et al., 2010). Of note, high values of IL-6 are associated with diuretic resistance in HF patients (Kielar et al., 2005; Zhang W. et al., 2012).

Higher IL-6 concentrations have been associated with worse clinical status in CHF patients, being an independent predictor of mortality (Tsutamoto et al., 1998; Maeda et al., 2000). In AHF, IL-6 values at 48–72 h were found to be independently
Interleukin 18

The proinflammatory cytokine interleukin 18 (IL-18) is a member of the IL-1 superfamily, being activated similarly to IL-1β by caspase-1 after inflammasome formation (Dinarello et al., 2013; O’Brien et al., 2014; Segiet et al., 2019a). IL-18 exists mostly as a soluble cytokine, although a membrane-bound form can also be found in a subset of macrophages, which can release soluble IL-18 upon stimulation with lipopolysaccharide (O’Brien et al., 2014). The receptor for IL-18 (IL-18R) is a dimer formed by the IL-18Rα chain, which is the low-affinity binding site for mature IL-18, and the IL-18R β chain, which binds the IL-18/IL-18Rα complex, thus forming a high-affinity complex that initiates signaling. These receptor subunits are members of the IL-1R family (Dinarello et al., 2013; O’Brien et al., 2014). Of note, the activation of the IL-18R requires higher amounts of IL-18 (10–20 ng/mL or higher) than the activation of IL-1R by IL-1α or IL-1β (frequently activated in the pg/mL range) (Dinarello et al., 2013). The activity of IL-18 is negatively regulated by IL-18 binding protein (IL-18BP), which is constitutively secreted and binds IL-18 with extremely high affinity (Dinarello et al., 2013). Since IL-18BP neutralizes the circulating IL-18, the concentration of the free form of IL-18 is lower than the total circulating IL-18 amount. Moreover, the values of free IL-18 appear to have a better correlation with disease activity than total IL-18 concentration (Dinarello et al., 2013; O’Brien et al., 2014; Kaneko et al., 2019).

In the heart, IL-18 induces an inflammatory response by increasing IFN-γ production by infiltrated neutrophils, resident macrophages and endothelial cells and by stimulating IL-1β and TNF-α generation by endothelial cells. IL-18 also increases the expression of vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) in endothelial cells and cardiomyocytes, thus increasing leukocyte recruitment into the injured myocardium and amplifying cardiac inflammation (Wang et al., 2008). IL-18 has also been shown to induce cardiac hypertrophy and fibrosis, apoptosis, contractile dysfunction and decreased β-adrenergic receptor responsiveness (Wang et al., 2008; O’Brien et al., 2014; Segiet et al., 2019a). Some of these effects appear to be mediated, at least in part, by the induction of other cytokines and chemokines, such as IL-1β, TNF-α, and IFN-γ (Wang et al., 2008; O’Brien et al., 2014).

The precursor form of IL-18 is constitutively expressed in several cell types such as monocytes, macrophages, epithelial cells, endothelial cells and cardiomyocytes (Dinarello et al., 2013; O’Brien et al., 2014; Segiet et al., 2019a). Following acute MI, the activation of the inflammasome in leukocytes, fibroblasts and cardiomyocytes in the ischemic myocardial tissue increases the local production of IL-18 (O’Brien et al., 2014). In the human failing ischemic myocardium, IL-18 was detected in endothelial cells, macrophages and cardiomyocytes (Mallat et al., 2004; Wang et al., 2008). Both the active and the precursor form of IL-18 protein were also shown to be highly expressed in human atherosclerotic plaque macrophages. Furthermore, IL-18 mRNA expression was higher in unstable than in asymptomatic plaques (Mallat et al., 2001).
Patients with acute MI also have raised systemic IL-18 concentrations which correlate with increased values of atrial natriuretic peptide (ANP), suggesting a role for IL-18 in ANP induction (Seta et al., 2000; O’Brien et al., 2014). Of note, higher IL-18 concentrations are associated with the development of congestive HF and acute MI in patients with acute coronary syndromes and with increased mortality in elderly patients with HF (O’Brien et al., 2014; Sanchez et al., 2014).

**Interleukin 33**

Interleukin 33 (IL-33) is a member of IL-1 cytokine family and was found to be the ligand for the ST2 receptor which belongs to the IL-1 receptor superfamily (Kunes et al., 2010; Altara et al., 2018; Ghali et al., 2018; Segiet et al., 2019a). The ST2 receptor exists as a functionally active transmembrane form (ST2L) and as a soluble “decoy” receptor form (sST2). sST2 is a mechanically induced cardiomyocyte protein that counteracts the anti-hypertrophic action of IL-33 and other IL-33/ST2L-mediated effects (Kunes et al., 2010; Altara et al., 2018; Ghali et al., 2018; Segiet et al., 2019a). There is considerable evidence that sST2 concentration may be used as an indicator of cardiac stress and remodeling in several cardiovascular diseases such as HF, cardiomyopathies, arterial hypertension and aortic stenosis (Ghali et al., 2018). There have been more studies evaluating sST2 than IL-33 because of its higher concentrations and stability (Altara et al., 2018).

IL-33 is constitutively expressed in endothelial cells of both small and large vessels, but not of brain or glomeruli microvessels. Epithelial cells, smooth muscle cells, fibroblasts and keratinocytes also constitutively express IL-33 (Altara et al., 2018; Segiet et al., 2019a). Adipose tissue and endothelial cells of human atherosclerotic plaque also express IL-33 (Demyanets et al., 2011; Ghali et al., 2018). In the heart, it is predominantly expressed in vascular endothelial cells, but it is also present in fibroblasts and cardiomyocytes, having a fivefold higher expression in fibroblasts than in cardiomyocytes (Kunes et al., 2010; Ghali et al., 2018). Of note, endothelial cells appear to be important to translate myocardial pressure overload into a systemic inflammatory response via IL-33 secretion (Chen et al., 2015). Mechanical strain is the main stimulus for the induction of IL-33 expression in the heart, although proinflammatory cytokines such as TNF-α, IL-1β, and IFN-γ also increase its production (Sanada et al., 2007; Kunes et al., 2010; Demyanets et al., 2013). IL-33 is also released during cell necrosis (Demyanets et al., 2013). Angiotensin II (Ang II) also induces IL-33, with both mediators exerting compensatory effects in response to increased cardiac stretch (Kunes et al., 2010).

In contrast to other members of the IL-1 family such as IL-1α, IL-1β and IL-18, IL-33 has predominantly an anti-inflammatory action since it is associated with T-helper type 2 (Th2) immune responses (Kunes et al., 2010). IL-33 exerts cardioprotective effects by reducing cardiomyocyte hypertrophy, cardiomyocyte loss by apoptosis, infarct size, cardiac remodeling and fibrosis (Kunes et al., 2010; Ghali et al., 2018; Segiet et al., 2019a). IL-33 also inhibits the formation of atherosclerotic plaque and reduces angiotensin II-induced ROS and lipid peroxidation products in human cardiomyocytes, an effect that may be attenuated by increased sST2 concentrations (Kunes et al., 2010; Zhang H.F. et al., 2012). However, IL-33 has also been shown to induce proinflammatory cytokines and adhesion molecules in endothelial cells, promoting vascular permeability and angiogenesis and contributing to the early endothelial dysfunction events involved in the development of atherosclerotic lesions (Choi et al., 2009; Demyanets et al., 2011; Pollheimer et al., 2013).

Some studies have shown that IL-33 concentrations are increased, positively correlated with TNF-α and N-terminal-pro-B-type-natriuretic peptide (NT-proBNP) and negatively correlated with LVEF in CHF patients (Zhang H.F. et al., 2012; Xiang et al., 2021). These effects might be due to a reduction of IL-33 bioactivity caused by the increase of sST2 in these patients (Zhang H.F. et al., 2012). Of note, sST2 concentrations are higher in HFREF than in HFP EF, being a predictor of adverse outcomes in both HF populations (Manzano-Fernandez et al., 2011; Song et al., 2020). In patients with acute worsening of HF, higher sST2 values were also shown to be useful to identify those patients at high-risk of in-hospital death (McCarthy and Januzzi, 2018; Borovac et al., 2020). sST2 concentrations rapidly decreased after hospital admission in AHF patients with uncomplicated short-term follow-up, while AHF patients that died within 6 months showed a significant increase of sST2 values after admission (Boisot et al., 2008; McCarthy and Januzzi, 2018). Furthermore, higher sST2 concentrations appear to be associated with lower diuretic efficiency in patients with AHF and concomitant renal dysfunction (Espriella et al., 2021).

In contrast to the studies describing an increase of IL-33 in human HF, a recent study showed reduced IL-33 concentrations in HFREF patients when compared to healthy controls, with patients with HF of ischemic etiology presenting lower values than those with non-ischemic etiology (Segiet et al., 2019b). More studies are needed to clarify whether IL-33 is cardioprotective or contributes to chronic inflammation, aggravating the disease (Altara et al., 2018; Segiet et al., 2019b).

**Myeloperoxidase**

Myeloperoxidase (MPO) is a haem-containing enzyme mainly secreted by neutrophils and monocytes, under inflammatory conditions, but has also been detected in other cell types such as macrophages (e.g., infiltrating macrophages in atherosclerotic lesions, peritoneal macrophages), CD4+ and CD8+ lymphocytes, endothelial cells and platelets (Ndrepepa, 2019; Sousa et al., 2019). MPO activity in macrophages probably results from neutrophils endocytosis or MPO internalization, while in endothelial cells, MPO may be endogenously expressed or originate from external sources (Ndrepepa, 2019). MPO uses H2O2 derived from leukocyte or vascular NADPH oxidases to produce several oxidizing molecules such as hypochlorous acid (HClO), chloramines, tyrosyl radicals and nitrogen dioxide (Ndrepepa, 2019; Sousa et al., 2019). These MPO-derived ROS and reactive nitrogen species (RNS) exert not only bactericidal effects, but also tissue damaging actions in the cardiovascular and renal systems and in the brain (Ndrepepa, 2019; Sousa et al., 2019; Correa et al., 2020). MPO significantly affects vascular tone, endothelial NO availability, being involved in atherogenesis and cardiovascular disease (Csato et al., 2015;
of myocardial infarction, evidencing a pathophysiological role of MPO in the development of CHF (Askari et al., 2020). In humans, CHF patients exhibit higher systemic MPO values, which appear to be associated with worse outcomes (Ng et al., 2006; Tang et al., 2006, 2007). Patients with AHF and CS also show markedly increased circulating MPO values (Reina-Couto et al., 2019b). In acutely decompensated CHF, MPO concentration was also associated with an increased risk for 1-year mortality (Reichlin et al., 2010).

**Inducible Nitric Oxide Synthase**

NO is a free radical involved in several physiological processes relevant for cardiovascular regulation, including vasodilation, regulation of cardiac contractility, modulation of sympathetic outflow, smooth muscle cell proliferation, regulation of renal renin release, natriuresis and immune response (Sousa et al., 2019; Cinelli et al., 2020). It is generated by the oxidation of L-arginine to L-citrulline by NO synthases (NOS), a family of enzymes composed of 2 constitutive isoforms, namely neuronal NOS (nNOS or NOS1) and endothelial NOS (eNOS or NOS3), and one inducible isoform (inducible NO synthase, iNOS or NOS2) (Tang et al., 2014; Sousa et al., 2019; Cinelli et al., 2020). iNOS is not normally produced in most cells, being only expressed after induction or stimulation, generally by proinflammatory cytokines (e.g., TNF-α; IL-1β; interferon gamma, IFN-γ) and lipopolysaccharide (Cinelli et al., 2020). After induction, iNOS generates high amounts of NO (100- to 1000-fold more NO than that produced by eNOS). This production persists for many hours until the enzyme is degraded (Soskic et al., 2011; Cinelli et al., 2020). Although these significant amounts of NO are important for the immune response, they can also contribute to toxic effects and to several human diseases, including HF (Soskic et al., 2011; Cinelli et al., 2020).

iNOS was originally discovered in macrophages but has been shown to be expressed in several cell types, including smooth muscle cells, endothelial cells, cardiomyocytes, hepatocytes, neurons, glial cell and astrocytes (Hemmrich et al., 2003; Cinelli et al., 2020). Regarding cardiac function, high concentrations of NO have been shown to exert negative inotropic and chronotropic effects and to reduce the response to β-adrenergic stimulation (Cotton et al., 2002). Importantly, under inflammatory conditions, the reaction of NO with ROS is favored, originating RNS such as peroxynitrite (Pacher et al., 2007). Both excess NO and peroxynitrite can cause deleterious effects in the heart, namely cell apoptosis, contractile dysfunction, irreversible reduction of myocardial oxygen consumption and dysregulation of heart rate and rhythm (Cotton et al., 2002; Kaluski et al., 2006; Pacher et al., 2007). The overexpression of iNOS also appears to contribute to myocardial fibrosis and ventricular hypertrophy (Zhang et al., 2007). iNOS has been detected in the hearts of CHF patients (NYHA classes III-IV), regardless of the etiology (Veijlstrup et al., 1998). Furthermore, it was shown to be uniformly distributed in the left and right ventricles and was primarily located in endothelial and vascular smooth muscle cells of the myocardial vasculature of these patients, being also found, although to a lesser extent, in the cardiomyocyte membrane (Veijlstrup et al., 1998). Infiltrating macrophages also account for iNOS expression in the post-ischemic failing heart (Kingery et al., 2017). Additionally, the activation of iNOS in peripheral vessels of CHF patients (NYHA classes II and III) was shown to be positively associated with systemic BNP concentration and appears to be an independent predictor for worsening HF (Ishibashi et al., 2008). Patients with decompensated CHF were also shown to have increased iNOS expression in peripheral mononuclear cells which was also positively correlated with plasma BNP values (Speranza et al., 2012). As previously mentioned, CS induces a systemic inflammatory response, iNOS activation and excessive production of NO which reduces myocardial contractility, suppresses mitochondrial respiration, attenuates the β-adrenergic inotropic response and induces inadequate systemic vasodilation, leading to systemic hypoperfusion (Kaluski et al., 2006; Shpektor, 2010). The overproduction of peroxynitrite also aggravates myocardial contractile dysfunction (Kaluski et al., 2006; Pacher et al., 2007).

**C-Reactive Protein**

C-reactive protein (CRP) is the best studied acute-phase protein. Its synthesis occurs mainly in the liver, being induced by raised IL-6 concentrations under conditions of infection, trauma and other inflammatory states (Huyhn et al., 2015; Sheriff et al., 2021). In humans, CRP values markedly increase in the first 72 h after tissue damage, being a sensitive yet non-specific biomarker of inflammation (Huyhn et al., 2015; Thiele et al., 2015). CRP is primarily present as a pentamer of five similar polypeptide subunits but can also dissociate into monomers. It is still under debate whether these pentameric and monomeric forms exert different functions. While circulating CRP is pentameric, local deposition of monomeric CRP has been detected in infarcted myocardial tissue, in brain tissue of stroke patients and in the kidney of diabetic patients with severe chronic kidney disease (Thiele et al., 2015; Sheriff et al., 2021).

CRP is a strong chemotaxin/opsonin for macrophages. It binds to phosphorylcholine groups in pathogens and also in non-healthy human cells (e.g., apoptotic, necrotic, energy-depleted, ischemic/hypoxic cells), marking these cells and consequently inducing their phagocytosis through complement activation (Sheriff et al., 2021). The phagocytosis of ischemic/hypoxic cells in the setting of acute myocardial infarction activates IL-6 production, which further induces more CRP, amplifying the immune response. Thus, CRP exacerbates tissue injury and scarring after a cardiovascular event (Griselli et al., 1999; Sheriff et al., 2021). CRP is also present in the myocardium of patients with non-ischemic HF, where it may contribute to myocardial damage through complement system activation and chemotaxis of macrophages (Zimmermann et al., 2009).

CRP can also be produced outside the liver, namely in vascular smooth muscle cells from human coronary arteries, respiratory epithelium, renal cortical tubular cells, neuronal cells, adipocytes and leukocytes (Huynh et al., 2015; Thiele et al., 2021).
CRP is an established independent cardiovascular risk factor, with higher CRP values being associated with major cardiovascular events and mortality and showing prognostic significance for risk stratification (Ridker et al., 2003; Koenig et al., 2006; Jan et al., 2008). Since traditional assays of CRP do not effectively detect basal CRP values, assays for the quantification of high-sensitivity CRP (hsCRP) were developed in order to improve risk stratification, with values below 1 mg/L, from 1 to 3 mg/L and higher than 3 mg/L corresponding to low-, moderate- and high-risk groups (Bassuk et al., 2004; Huynh et al., 2015).

Increased CRP values appear to be a predictor for HF development in high-risk populations (Vasan et al., 2003). CRP values higher than 3.23 mg/L are associated with higher HF severity evidenced by lower LVEF, higher NYHA functional classes, higher heart rate and increased prevalence of atrial fibrillation (Anand et al., 2005). In AHF, CRP values are increased by fivefold at admission when compared to the concentrations found in CHF patients. Elevated CRP is also related with worse prognosis in ADHF patients and CRP values above 12 mg/L are associated with increased risk of death and HF readmissions within 3 months (Michelucci et al., 2007; Lourenco et al., 2010).

The major effects of these inflammatory mediators with relevance for HF pathophysiology are summarized in Figures 1, 2.

**ANTI-INFLAMMATORY STRATEGIES IN HUMAN HEART FAILURE**

Several direct or indirect anti-inflammatory therapies have been tested in HF patients. Direct therapies include anti-cytokines, prednisone or colchicine, while indirect strategies repurposed drugs that were previously evidenced to exert pleiotropic anti-inflammatory/immunomodulatory effects.

**Anti-cytokine Therapies**

Direct anti-inflammatory therapies have yielded conflicting results. Both anti-TNF-α drugs, namely etanercept (Mann et al., 2004) and infliximab (Chung et al., 2003) are now well accepted to be contraindicated in HF, at least in these high-intensity schemes (Adamo et al., 2020; Murphy et al., 2020). The contradictory results between preclinical, observational, preliminary data and the bigger randomized trial might be due to the abolishment of cardioprotective effect of NF-κB, a downstream effector of TNF-α, as well as to the demonstrated infliximab apoptotic and lytic properties (Horii and Yamaguchi, 2013). On the other hand, anti-IL-1 strategy seems more promising. First, anakinra, an IL-1 receptor antagonist, was shown to improve exercise capacity in both small trials in HFrEF (Van Tassell et al., 2012; Abbate et al., 2013) and HFpEF (Van Tassell et al., 2014) but in longer courses in AHF (Van Tassell et al., 2017) it decreased the composite of death or hospitalization for HF; second, canakinumab, a recombinant human monoclonal antibody that targets IL-1β, when added to optimal statin therapy (Ridker et al., 2017), reduced the risk of the composite end point of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death compared with placebo. It showed greater benefit in a dose and hsCRP-dependent fashion, a surrogate biomarker of IL-1 activity, confirming the concept of personalized treatment in HF (Ridker et al., 2018). Nevertheless, although the neutralization of IL-1β or the blockade of IL-1RI were shown to be protective in human CHF and AHF (Van Tassell et al., 2012; Abbate et al., 2013; Van Tassell et al., 2014, 2016, 2017; Cavalli et al., 2017; Cavalli et al., 2017; Buckley et al., 2018; Everett et al., 2019), circulating IL-1β values are frequently below detection limits, being very difficult to establish a correlation between IL-1β concentration and disease severity (Abbate et al., 2020).

For anti-IL-6 therapy, we still have to wait for major HF trials, with preliminary data in rheumatoid arthritis and in NSTEMI patients showing encouraging results (Kobayashi et al., 2014; Kleveland et al., 2016; Yokoe et al., 2018), as well as for the anti-IL-12/-23 therapy where treatment with ustekinumab in patients with psoriasis was associated with improved echocardiographic measures, lower IL-6 and NT-proBNP (Ikonomidis et al., 2017).

Anti-IL-8 treatment has not been evaluated yet in HF patients, although an antibody targeting IL-8 (BMS-986253) is being tested in clinical trials involving patients with malignant tumors or patients with COVID-19 (Bilusic et al., 2019; Dallos, 2020). Of note, since IL-8 expression is redox regulated (Apostolakis et al., 2009), antioxidants may be useful to therapeutically modulate IL-8 concentrations.

Regarding IL-10 therapy, although its administration was shown to exert cardioprotective effects in animal models (Krishnamurthy et al., 2009; Verma et al., 2012), it has not been tested yet in HF patients.

Therapies targeting IL-18 have been tested in other clinical conditions, but not in HF patients. In patients with type 2 diabetes mellitus or in patients undergoing renal transplantation, trials with a IL-18 neutralizing antibody (GSK1070806) did not show evidence of clinical benefits (McKie et al., 2016; Wlodek et al., 2021). More recently, a clinical trial with a recombinant human IL-18 BP (tadefkinig alfa), as well as a short report of a prolonged treatment with this therapy, showed signs of efficacy in patients with a rare systemic autoinflammatory disease (Gabay et al., 2018; Kiltz et al., 2020). With respect to IL-33, it remains to clarify whether it is mainly cardioprotective or contribute to endothelial inflammation, aggravating cardiovascular diseases (Altara et al., 2018; Segiet et al., 2019b). Trials with anti-IL-33 antibodies (etokimab and SAR440340) have been conducted in asthma and atopic dermatitis patients, showing disease improvement with these treatments (Donovan and Hansbro, 2020). Astegolimab,
FIGURE 1 | Effects of major cytokines contributing to heart failure pathophysiology. DNA, deoxyribonucleic acid; ENaC, epithelial sodium channel; ET-1, endothelin-1; ICAM-1, intercellular adhesion molecule 1; IFN-γ, interferon gamma; IL-1, interleukin 1; IL-1β, interleukin 1 beta; IL-6, interleukin 6; IL-8, interleukin 8; IL-10, interleukin 10; IL-18, interleukin 18; IL-33, interleukin 33; NO, nitric oxide; NOS, nitric oxide synthase; iNOS, inducible nitric oxide synthase; ROS, reactive oxygen species; SERCA2, sarcoplasmic/endoplasmic reticulum calcium ATPase 2; TNF-α, tumor necrosis factor alpha; VCAM-1, vascular cell adhesion molecule 1; VSMCs, vascular smooth muscle cells.
FIGURE 2 | Effects of other important inflammatory mediators contributing to heart failure pathophysiology. CRP, C-reactive protein; CS, cardiogenic shock; ET-1, endothelin-1; iNOS, inducible nitric oxide synthase; LDL, low density lipoprotein; MCP-1, monocyte chemoattractant protein-1; MPO, myeloperoxidase; NO, nitric oxide; NOS, nitric oxide synthase; PAI-1, plasminogen activator inhibitor 1; VSMCs, vascular smooth muscle cells.

an anti-ST2 antibody that selectively inhibits the IL-33 receptor, was also tested in asthmatics, being able to reduce asthma exacerbation rate (Kelsen et al., 2021). So far, therapies targeting the IL-33/ST2L/sST2 axis have not been tested in human cardiovascular diseases.

Nitric Oxide Synthases Inhibitors
The role of nitrates and NOS is not unanimous in HF. While in HFrEF, direct donors of NO have its place, at least in patients with optimized treatment or in those not tolerating first line options (Farag et al., 2015) or in ischemic or black patients (Taylor et al., 2004; Real et al., 2018), in AHF, the GALACTIC study failed to demonstrate the improvement in all-cause mortality and re-hospitalization with the early intensive and sustained treatment with nitrates (Kozhuharov et al., 2019).

On the contrary, adjunctive use of NOS inhibition in the setting of CS, based on the theory of overproduction of NO by activated iNOS secondary to systemic inflammatory response (Hochman, 2003), was enthusiastic once again in small single-center trials (Cotter et al., 2000, 2003) with L-NMMA (NG-monomethyl L-arginine), a competitive non-specific NOS inhibitor. However, this was not confirmed in the randomized multi-centre trial SHOCK-2 (Dzavik et al., 2007) nor in TRIUMPH trial (TRIUMPH Investigators et al., 2007), which tested another pan-NOS inhibitor (Kaluski et al., 2006). This lack of clinical benefit might have been caused by the inhibition of constitutive NOS isoforms, which contribute to protective effects on vascular tone and microcirculation, promote ventricular relaxation and prevent platelet adhesion and aggregation (Bailey et al., 2007; TRIUMPH Investigators et al., 2007; Shpekter, 2010). Furthermore, the peroxynitrite-mediated effects are not readily reversible by the acute treatment with NOS inhibitors (Cotton et al., 2002). Nevertheless, newer strategies focusing on the specific inhibition of iNOS or on drugs targeting nitrosative stress should also be tested (Shpekter, 2010).

Other Anti-inflammatory Therapies
The results of indirect anti-inflammatory therapies have as well to be considered. Statins possess pleiotropic properties, namely antioxidant, angiogenic, immunomodulatory, and also anti-inflammatory effects (Costa et al., 2016) evidenced by the reduction of CRP concentrations independently of lipid reduction (Jain and Ridker, 2005). Again, the observational and post hoc analyses data derived from TNT and PROVE-IT studies (Scirica et al., 2006; Khush et al., 2007) and the randomized trials UNIVERSE (Krum et al., 2007), CORONA and GISSI-HF showed neutral effects (Kjekshus et al., 2007; Tavazzi et al., 2008b). Nevertheless, the individualized use of these drugs in patients with atherosclerosis and high LDL-cholesterol could magnify beneficial effects against detrimental
inhibition of CoQ10 synthesis that intensifies hypertrophy, especially with high doses of statins in patients with long-term HF (Niazi et al., 2020).

In CHF patients, CRP concentration has also been shown to be reduced by other drugs such as β-blockers (carvedilol) and angiotensin II receptor antagonists (valsartan), but not by the combination of valsartan with angiotensin converting enzyme inhibitors (Anand et al., 2005; Nessler et al., 2013). In addition, in AHF patients, significantly decreased hsCRP concentrations were observed at 30 days after short-term inotropic support (White et al., 2006). However, the putative effect of hsCRP reduction on mortality could not be demonstrated due to the small sample size (Huynh et al., 2015). In acute settings, CRP values need to be rapidly lowered and this cannot be achieved by using CRP-lowering drugs that take several days to influence CRP concentrations (Pepys et al., 2006; Jones et al., 2012; Szalay et al., 2014). This problem can be solved by CRP apheresis, which removes CRP from the blood plasma after myocardial infarction, significantly reducing the infarct area and improving LVEF (Ries et al., 2018, 2019; Mattecka et al., 2019).

Noteworthy, the GISSI-HF study opened new possibilities as the first large scale clinical trial testing omega-3 fatty acids, that when adding 1 g daily to the best medical treatment offered a modest but significant reduction on all-cause mortality and CV hospitalization and proved to be a safe option (Tavazzi et al., 2008a). In a subsequent trial, the reduction seen in inflammatory markers (Moertl et al., 2011), like IL-6 and TNF-α, in the high dose of 4g/d regimen, accompanied by a dose-dependent increase of LVEF and improvement of endothelial function, could justify the outcome benefits. Recent trials, like MESA cohort (Block et al., 2019), showed a significant independent inverse correlation between circulating levels of omega-3 fatty acids, specifically eicosapentaenoic acid (EPA), and the occurrence of HF over a long median follow-up period of 13 years, as well as the ability of plasma EPA concentrations to predict the occurrence of HF in all ethnicities. Also, in the REDUCE-IT trial, very high plasma values of omega-3 fatty acids were associated with a reduction of major CV events (Bhatt et al., 2019) and in the OMEGA REMODEL trial (Heydari et al., 2016), a 6-month treatment with 4 g daily of omega-3 fatty acids on top of the current guideline-based standard of care was associated with a reduction of adverse left ventricular remodeling, myocardial fibrosis and serum biomarkers of systemic inflammation, namely MPO and ST2. Interestingly, EPA is also the precursor of resolvin E1 (RvE1), one of the specialized resolvins, which could directly contribute to resolution of inflammation. Experimental studies have already shown that RvE1, through its receptor ChemR23, exerts a direct protective effect on cardiomyocytes against ischemia-reperfusion injury and limits infarct size when administered intravenously before reperfusion (Keyes et al., 2010; Reina-Couto et al., 2016; Carracedo et al., 2019). Preliminary studies of our group, conducted in patients with AHF and CS, also demonstrated that RvE1 is increased in AHF and CS and correlated with CRP and MPO (Reina-Couto et al., 2019a).

Despite several lines of evidence indicating an association between increased MPO concentrations and HF pathogenesis and severity, the clinical benefit of MPO inhibition in HF patients remains unknown (Ng et al., 2006; Tang et al., 2006, 2007; Reichlin et al., 2010; Ndrepepa, 2019). A clinical trial is currently evaluating the hemodynamic effects of an oral MPO inhibitor, AZD4831, following baseline, resting and exercise testing in HFpEF patients during right heart catheterization (Gan et al., 2019; Nelander et al., 2021).

Serum uric acid (UA) is widely recognized as a biomarker of oxidative stress in several cardiovascular diseases, including HF (Anker et al., 2003). After cellular damage, increased amounts of available xanthine and hypoxanthine can be converted into UA by xanthine oxidase (XO), upregulated itself in cardiovascular disease. Since XO uses oxygen as an electron acceptor, ROS are also generated, contributing to oxidative stress (Zimmet and Hare, 2006; Sousa et al., 2019). Although several studies and meta-analyses have identified elevations of serum UA as an independent marker of poor prognosis in HF patients (Jankowska et al., 2007; Tamariz et al., 2011) and pre-clinical (Stull et al., 2004) and case-control studies (Gotsman et al., 2012), as well as the later OPT-HF study (Hare et al., 2008), showed that XO inhibition was associated with improved survival in HF, the EXACT-HF trial failed to demonstrate a clinical benefit of high-dose allopurinol in HFpEF patients with increased UA concentrations. This lack of benefit might have resulted from the short duration of this study. The authors also suggested that serum UA might be just a marker of disease severity and prognosis and not a target for therapy, even though there was trend toward lower hospitalizations in the allopurinol group of this study. Other possible explanation is that other metabolic pathways, not targeted by the selective inhibition of XO, may be responsible for the nitroso-redox imbalance, as suggested by the unchanged concentrations of MPO in these patients (Tamariz and Hare, 2015).

**Immunomodulators**

Other strategies based not only on classic anti-inflammatory schemes, but in a new concept of modulation of inflammation, as shown by the small trials with intravenous immunoglobulin (IVIg), pentoxifylline and thalidomide or the recent repurposed colchicine, could have a role in HF management. IVIg preparations are known to have anti-infectious, anti-inflammatory, and immunomodulatory properties (Nimmerjahn and Ravetch, 2008), but recent prospective, randomized, double-blind, placebo-controlled trial to evaluate the effect of IVIg on systemic cardiac function in adult patients with idiopathic chronic dilated cardiomyopathy (DCM) and parvovirus cardiac B19V persistence (Hazebroek et al., 2021) did not demonstrate improvement of cardiac systolic function or functional capacity beyond standard medical therapy. Importantly, nor even Gullestad et al. (2001a, 2013) could confirm the IVIg protective effects, years later after their study in 2001, in ischemic patients. This treatment is nowadays reserved as an alternative therapy to myocarditis and inflammatory cardiomyopathy in combination with immunoadsorption (Tschope et al., 2021), which still needs validation in multi-center, double blind studies (Bian et al., 2021). The same author, Gullestad et al. (2005), trying the same rationale of beneficial effects of immunomodulation in HF patients, also tested thalidomide. While immunoregulatory
TABLE 1 | Trials targeting major inflammatory mediators of HF.

| Target | Trial acronym/registry number and Reference | Study design | Study population | Intervention | Drug mechanism of action | Follow-up | Outcomes |
|--------|---------------------------------------------|--------------|------------------|--------------|--------------------------|-----------|----------|
| TNF-α  | Deswal et al., 1999                         | Randomized double-blind | 18 HFrEF patients with NYHA class III (United States) with LVEF of <35% | Intervention groups: single intravenous infusion of 1, 4, or 10 mg/m² of etanercept over 30 min (n = 4 for each dose) Placebo group (n = 6) | TNF-α inhibitor (dimeric recombinant protein fusing the TNF receptor 2 to the Fc region of the human IgG1 antibody) | 14 days | - No adverse effects  
- 4 or 10 mg/m² of etanercept: ↓ TNF-α, IL 6  
↑ quality of life, 6-min walk test distance and ejection fraction |
|        | Bozkurt et al., 2001                        | Randomized, double-blind, placebo-controlled | 47 HFrEF patients with NYHA class III to IV (United States) with LVEF of <30% | Intervention groups: subcutaneous injections of etanercept 5 mg/m² (n = 16) or 12 mg/m² (n = 15) twice weekly for 3 months Placebo group (n = 16) | TNF-α inhibitor (dimeric recombinant protein fusing the TNF receptor 2 to the Fc region of the human IgG1 antibody) | 3 months | - Safe treatment;  
- Dose-dependent improvement in LV structure, remodeling and function |
|        | Fichttscherer et al., 2001                  | Randomized | 18 patients with CHF (Germany) with LVEF of <30% | Intervention group (n = 13): single dose of subcutaneous injection of 25 mg etanercept Control group (n = 5) | TNF-α inhibitor (dimeric recombinant protein fusing the TNF receptor 2 to the Fc region of the human IgG1 antibody) | 7 days | - Improved systemic endothelial vasodilator capacity;  
- Positive correlation between the increase in ACh-induced-forearm blood flow responses and baseline TNF-α serum values |
|        | ATTACH (Anti-TNF Therapy Against Congestive Heart Failure Trial) (Chung et al., 2003) | Randomized double-blind | 150 HFrEF patients with stable NYHA class III or IV (United States) with LVEF of ≤35% | Intervention groups: 2-h intravenous infusion of infliximab 5 mg/kg (n = 51) at 0, 2 and 6 weeks Placebo group (n = 49) | TNF-α inhibitor (Anti-TNF-α, mouse-human chimeric monoclonal antibody) | 28 weeks | - No improvement in clinical status  
- 10 mg/kg infliximab: ↑ risk of death or hospitalization  
- 5 mg/kg infliximab: ↓ CRP, IL-6; ↑ EF (modestly) |
|        | RENEWAL (Randomized Etanercept Worldwide Evaluation): combined data of RENAISSANCE and RECOVER trials in a pre-specified study (Marr et al., 2004) | Randomized double-blind, placebo-controlled | 1673 patients with CHF (United Kingdom, Sweden, Germany, Holland, Denmark, Italy, France, Norway, Israel, Australia, New Zealand, United States) with LVEF of <30% | Intervention groups: etanercept subcutaneous injection 25 mg 3x weekly (n = 308), 25 mg 2x weekly (n = 683) Placebo group (n = 682) | TNF-α inhibitor (dimeric recombinant protein fusing the TNF receptor 2 to the Fc region of the human IgG1 antibody) | 24 weeks | - No effects on the rate of death or hospitalization |
| IL-1   | D-HART (Diastolic Heart failure Anakinra Response Trial) NCT01542502 (Van Tassell et al., 2014) | Randomized, double blind, placebo-controlled, crossover pilot study | 12 patients with HFP EF (United States) | SC injection of 100 mg of anakinra daily for 14 days and an additional 14 days of placebo or SC injection of placebo daily for 14 days and 100 mg of anakinra for an additional 14 days 100 mg anakinra twice daily for 3 days followed by once daily for 11 days or matching placebo | Inhibits IL-1 binding to the IL-1 type I receptor (recombinant, non-glycosylated form of the endogenous IL-1 receptor antagonist peptide) | 28 days | - ↓ systemic inflammatory response  
- ↑ aerobic exercise capacity of patients with HFP EF and elevated plasma CRP levels |
|        | NCT01936844 (Van Tassell et al., 2016)      | Randomized double-blind placebo-controlled pilot study | 30 patients with ADHF (United States) with LVEF of <40% | | Inhibits IL-1 binding to the IL-1 type I receptor (recombinant, non-glycosylated form of the endogenous IL-1 receptor antagonist peptide) | 14 days | - ↓ systemic inflammatory response in patients with ADHF |
|        | CANTOS (Canakinumab anti-Inflammatory Thrombosis Outcome Study) NCT01327846 (Ricker et al., 2017) | Randomized, double-blind trial | 10,061 patients with previous MI and hsCRP ≥ 2 mg/L (North America, South America, Europe, Asia, Africa, Australia) | 3 doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) | IL-1β inhibitor (monoclonal antibody which binds to human IL-1β, blocking its interaction with IL-1 receptors) | 48 months | - ↓ rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering; ↑ incidence of fatal infection than placebo |

(Continued)
### TABLE 1 (Continued)

| Target | Trial acronym/registry number and Reference | Study design | Study population | Intervention | Drug mechanism of action | Follow-up | Outcomes |
|--------|-------------------------------------------|--------------|------------------|--------------|--------------------------|-----------|----------|
| REDHART (Recently Decompensated Heart Failure Anakinra Response Trial) NCT01936909 (Van Tassell et al., 2017) | Randomized in one of 3 treatment duration arms | 60 patients with recently decompensated systolic HF (United States) with LVEF of <50% | 1:1:1 ratio to 1 daily subcutaneous injections with anakinra 100 mg for 2 weeks, 12 weeks, or placebo | Inhibits IL-1 binding to the IL-1 type I receptor (recombinant, non-glycosylated form of the endogenous IL-1 receptor antagonist peptide) | 24 weeks | ↓ serum CRP values | ↑ peak VO2 in the group receiving anakinra for 12 weeks. |
| D-HART2 (Diastolic Heart Failure Anakinra Response Trial 2) NCT02173548 (Van Tassell et al., 2018) | 2:1 phase 2, randomized, double-blind, placebo-controlled | 31 patients with HFpEF (Sweden) | IL-1 blockade with anakinra: 100 mg subcutaneously daily (n = 21) or placebo (n = 10) for 12 weeks | Inhibits IL-1 binding to the IL-1 type I receptor (recombinant, non-glycosylated form of the endogenous IL-1 receptor antagonist peptide) | 24 weeks | ↓ serum hsCRP values | ↓ serum NT-pro-BNP |
| IL-6 | Kobayashi et al., 2014 Pilot study | 20 women with rheumatoid arthritis (RA) without cardiac symptoms (Japan) | Tocilizumab (TCZ; 8 mg/kg IV every 4 weeks) prescribed for patients with RA with an inadequate clinical response to methotrexate | IL-6 inhibitor (anti-IL-6 receptor monoclonal antibody which binds to soluble and membrane-bound IL-6 receptors, inhibiting IL-6 signaling) | 52 weeks | ↑ increased EF | ↓ LVMI associated with disease activity | regression of LV eccentric hypertrophy |
| IL-6 | NCT01491074 (Kleveland et al., 2016) Two-center double-blind, randomized, placebo-controlled phase 2 trial | 117 patients with non-ST-elevation myocardial infarction (Norway) | Single dose (intravenous infusion) of the anti-IL-6R antibody tocilizumab 280 mg or matching placebo | IL-6 inhibitor (anti-IL-6 receptor monoclonal antibody which binds to soluble and membrane-bound IL-6 receptors, inhibiting IL-6 signaling) | 3 and 6 months | ↓ inflammatory response | primarily PCI-related TnT release in NSTEMI patients |
| Yokoe et al., 2018 | 70 patients with RA free of cardiovascular disease | Tocilizumab prescribed for patients with active RA - 8 mg/kg of intravenous TCZ every 4 weeks during 24 weeks | IL-6 inhibitor (anti-IL-6 receptor monoclonal antibody which binds to soluble and membrane-bound IL-6 receptors, inhibiting IL-6 signaling) | 24 weeks | ↓ NT-pro-BNP levels |
| RESCUE (Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition) NCT03926117 (Ridker et al., 2021) | Randomized, double-blind, phase 2 trial (at 40 clinical sites) | 264 participants with moderate-to-severe CKD and hsCRP ≥ 2 mg/L (high CV risk) (United States) | 66 were randomly assigned to each of the four treatment groups (1:1:1:1) to subcutaneous administration of placebo or ziltivekimab 7.5, 15, or 30 mg every 4 weeks | IL-6 inhibitor (monoclonal antibody directed against the IL-6 ligand) | 24 weeks | ↓ hsCRP values | ziltivekimab was well tolerated |
| MPO Hemodynamic Effects of a Novel Myeloperoxidase Inhibitor With Exercise in Heart Failure With Preserved Ejection Fraction - A Randomized, Double-Blind, Placebo Controlled Proof of Principle Study NCT03611153 | Randomized, double-blind, placebo controlled proof of principle study | 30 HFpEF patients referred to the catheterization laboratory for evaluation of breathlessness or shortness of breath | A single administration dose of 30 mg oral MPO inhibitor (AZD4831) or placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization. | Potent and selective MPO inhibitor | 9–14 days after the study drug dosage | Ongoing study |
| Study design | Study population | Intervention | Drug mechanism of action | Follow-up | Outcomes |
|--------------|------------------|--------------|--------------------------|-----------|----------|
| CRP          | CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) (Kjaekhus et al., 2007) | Single-blind, randomized, placebo controlled 5,011 II–IV NYHA class ischemic HFrEF patients (371 sites in 19 European countries, Russia, and South Africa) with LVEF of <35% | Intervention group (n = 2514): rosuvastatin 10 mg daily treatment for at least 3 months or placebo (n = 2497) | HMG-CoA reductase inhibitor with pleiotropic actions (e.g., antioxidant, anti-inflammatory, improvement of endothelial function) | 32.8 months | ↓ CRP values if HFrEF, no effect on composites of cardiovascular-related death, non-fatal MI or stroke; ↓ hsCRP values at 3 months; No effect on all-cause death or composite of all-cause death or hospitalization for cardiovascular causes |
| GISSI-HF     | (Gruppo Italiano Per Lo Studio Della Sopravivenza Nell’Insufficienza Cardiaca-Heart Failure) NCT00338336 (Tavazzi et al., 2008b) | Randomized, double-blind, placebo-controlled 4,574 II–IV NYHA class ischemic and dilated cardiomyopathy HFrEF patients (Italy) with mean LVEF of <45% | Intervention group (n = 2285): rosuvastatin 10 mg daily treatment for at least 3 months or placebo (n = 2289) | HMG-CoA reductase inhibitor with pleiotropic actions (e.g., antioxidant, anti-inflammatory, improvement of endothelial function) | 46.8 months | ↓ CRP values at 3 months; No effect on all-cause death or composite of all-cause death or hospitalization for cardiovascular causes |
| NOS          | Cotter et al., 2000 | Single-center, preliminary report 11 patients with extensive MI complicated with CS (Israel) | L-NMMA - 1 mg/kg bolus and 1 mg/kg/h continuous IV drip for 5 h | Non-selective NOS inhibitor | 1–3 months | No adverse effects; ↑ BP; ↑ Urinary output |
| LINCS        | (L-NAME [a NO synthase inhibitor] In the treatment of refractory Cardiogenic Shock) (Cotter et al., 2003) | Single-center, prospective randomized study 30 patients with refractory CS (Israel) | Intervention group (n = 15): supportive care in addition to L-NAME - 1 mg/kg bolus and 1 mg/kg/h continuous IV drip for 5 h; Control group (n = 15): supportive care alone | Non-selective NOS inhibitor | 4 months | No adverse effects; ↑ BP at 15 min (modestly); No effect on BP at 2 h; No effects on glucose and urinary output; No significant differences on mortality at 30 days |
| SHOCK-2      | (Should we inhibit nitric Oxide synthase in Cardiogenic Shock 2) (Dzavik et al., 2007) | Multicenter phase II, randomized, placebo-controlled, dose ranging study 79 patients with acute MI complicated by persistent CS despite PCI (United States, Canada, Germany, Israel, Austria, Denmark) | L-NMMA - 0.15/0.5/1.0/1.5 mg/kg IV bolus and 0.15/0.5/1.0/1.5 mg/kg/h infusion for 5 h; Placebo group (n = 20): 0.9% normal saline IV bolus, and 5 h infusion. | Non-selective NOS inhibitor | 2 h after study initiation | No adverse effects; ↑ BP at 15 min (modestly); No effect on BP at 2 h; No effects on glucose and urinary output; No significant differences on mortality at 30 days |
| TRIUMPH      | (Tilarginine Acetate Injection in a Randomized International Study in Unstable MI Patients With Cardiogenic Shock) (TRIUMPH Investigators, 2007) | International multicenter, randomized, double blind placebo-controlled 398 patients with refractory CS complicating MI despite PCI (eight countries in North America and Europe) | Intervention group (n = 206): Tilarginine (L-NMMA) - 1 mg/kg bolus and 1 mg/kg/h infusion for 5 h; Placebo group (n = 190). | Non-selective NOS inhibitor | 6 months | No effect on 30-day all-cause mortality; ↑ SBP at 2 h; No effect on the resolution of shock, on reinfarction, or on renal function. |

ACh, acetylcholine; ADHF, acute decompensated heart failure; BP, blood pressure; CHF, chronic heart failure; CKD, chronic kidney disease; CRF, cardiorespiratory fitness; CRP, C-reactive protein; CS, cardiogenic shock; CV, cardiovascular; EF, ejection fraction; HF, heart failure; HFrEF, Heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HMG-CoA, 3-hydroxy-3-methylglutaryl Coenzyme A; hsCRP, high sensitive C reactive protein; IL-1, interleukin 1; IL-6, interleukin 6; IL-6R, interleukin 6 receptor; L-NAME, N-Nitro-L-Arginine-Methyl Ester; L-NMMA, N-monomethyl-L-arginine; LV, left ventricular; LVMI, left ventricular mass index; MI, myocardial infarction; MPO, myeloperoxidase; NOS, nitric oxide synthase; NSTEMI, non-ST segment elevation myocardial infarction; NT-pro-BNP, N-terminal-pro-B-type Natriuretic Peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; RA, rheumatoid arthritis; SBP, systolic blood pressure; SC, subcutaneous; sICAM-1, soluble intercellular adhesion molecule-1; TCZ, tocilizumab; TNF-α, tumor necrosis factor alpha; TnT, troponin T; VO2, volume of oxygen consumption.
| Trial acronym/registry number and Reference | Study design | Study population | Intervention | Drug mechanism of action | Follow-up | Outcomes |
|--------------------------------------------|--------------|------------------|--------------|--------------------------|-----------|----------|
| Gullestad et al., 2001a                    | Randomized, double-blind, placebo-controlled study | 40 II–III NYHA class ischemic and dilated cardiomyopathy HFrEF patients with LVEF of <40% (Norway) | Intravenous immunoglobulin therapy (IVIG) - induction therapy (1 daily infusion at 0.4 g/kg for 5 days) and thereafter as monthly infusions (0.4 g/kg) for a total of 5 months or placebo for a total period of 26 weeks (4 weeks after last IVIG or placebo infusion). | Immunomodulator (influences the concentration of cytokines and cytokine modulators; neutralizes microbial antigens and autoantibodies; Fc-receptor blockade; complement inactivation) | 6 months | ↑ anti-inflammatory cytokine profile (IL-10, IL-1 receptor antagonist, and soluble tumor necrosis factor receptors) - improvement in clinical status | |
| Sliwa et al., 2002                         | Prospective, randomized, double-blind, placebo-controlled study | 18 IV NYHA class dilated cardiomyopathy HFrEF patients (South Africa) with LVEF of <25% | 1-month therapy with pentoxifylline (400 mg 3 times daily) (n = 9) and placebo (n = 9) | Immunomodulator (phosphodiesterase inhibitor leading to ↑cAMP and downstream inhibition of proinflammatory mediators) | 1 month | ↓ TNF-α levels and Fas/Apo-1 concentrations - improved symptoms and ↑ LVEF |
| Sliwa et al., 2004                         | Single-center, prospective, double-blind, placebo-controlled study | 38 II–III NYHA class ischemic HFrEF patients (South Africa) with LVEF of <35% | 2 parallel arms: pentoxifylline 400 mg TID (n = 20) or a matching placebo (n = 18) for 6 months in addition to standard therapy | Immunomodulator (phosphodiesterase inhibitor leading to ↑cAMP and downstream inhibition of proinflammatory mediators) | 6 months | ↓ in plasma markers of inflammation, prognosis, and apoptosis. - improved symptoms and ↑ LVEF |
| Gullestad et al., 2005                     | Double-blind, placebo-controlled study | 58 II–III NYHA class ischemic and dilated cardiomyopathy HFrEF patients (Norway) with LVEF of <40% | Thalidomide (25 mg QD increasing to 200 mg QD) or placebo and followed up for 12 weeks | Immunomodulator (alters the concentration of inflammatory cytokines; downregulates neutrophils) | 3 months | ↓ total neutrophil count and ↑ TNF-α levels - ↓ heart rate - ↑ in LVEF and improvement in left ventricular remodeling with matrix-stabilizing net effect |
| Gong et al., 2006                          | Prospective, randomized, placebo-controlled, single-blind study | 71 patients with CHF outpatients receiving conventional treatment (China) with LVEF of <35% | Intervention group (n = 35): Methotrexate 7.5 mg per week for 12 weeks Placebo group (n = 36) | Folate analog with anti-inflammatory properties: inhibits inflammatory cell proliferation; ↑ extracellular concentrations of adenosine (which exerts anti-inflammatory effects by binding to A2 receptors) | 12 weeks | ↓ TNF-α, IL-6, MCP-1, sICAM-1, CRP - ↑ IL-10, soluble IL-1 receptor antagonist - Improved NYHA functional class, 6-min walk test distance and quality of life scores |
| GISSI-HF (Gruppo Italiano Per lo Studio Della Sopravivenza Cardiaca-Heart Failure) NCT00336336 | Randomized, double-blind, placebo-controlled study | NYHA functional class II–IV heart failure irrespective of cause and/or LVEF (Italy) with mean LVEF of <45% | Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA) 1 g daily (n = 3494) vs. placebo (n = 3481) | Precursors of SPMs (which have proresolving and anti-inflammatory effects). Incorporation of n-3 PUFA on the membrane of target cells likely reduces electrical excitability (anti-arrhythmic effect). | 46.8 months | ↓ in both all-cause mortality and the composite end point of all-cause mortality and hospitalization for cardiovascular causes in all the predefined subgroups, compared with the placebo group |

(Continued)
| Trial acronym/registry number and Reference | Study design | Study population | Intervention | Drug mechanism of action | Follow-up | Outcomes |
|--------------------------------------------|-------------|------------------|--------------|--------------------------|-----------|----------|
| METIS (METhotrexate Therapy on the Physical Capacity of Patients With Ischemic Heart Failure Trial) (Moreira et al., 2009) | Randomized double-blind, placebo-controlled trial | 50 patients with ischemic CHF (Brazil) with mean LVEF of <45% | Intervention group (n = 25): Methotrexate 7.5 mg per week plus folic acid (5 mg/week) for 12 weeks Placebo group (n = 25): Placebo plus folic acid (5 mg/week), for 12 weeks | Folate analog with anti-inflammatory properties: inhibits inflammatory cell proliferation; ↑ extracellular concentrations of adenosine (which exerts anti-inflammatory effects by binding to $A_2$ receptors) | 12 weeks | - No effects on CRP - No effects on 6-min walk test distance - Trend toward improved NYHA scores |
| COPE-ADHF (Cardiac Outcome Prevention Effectiveness of Glucocorticoids in Acute Decompensated Heart Failure) (Liu et al., 2014) | Non-blinded randomized | 102 patients with ADHF (China) with mean LVEF of <45% | Intervention group: dexamethasone (20 mg/d) IV followed by prednisone (orally, daily, 1 mg/kg/d with a maximum dose of 60 mg/d) for 7 days and then tapered off in 3 days (n = 51); Control group (n = 51): standard care | Glucocorticoid receptor agonists that regulate the transcription of several genes involved in the inflammatory response. Also ↑ the expression of the receptor for natriuretic peptides (diuretic effect), | 30 days | - Safe therapy; - ↓ Serum creatinine - ↑ Diuresis, ↓ weight - ↓ CV death at 30 days - Improved dyspnea and clinical status |
| Deftereos et al., 2014 | Single-center, prospective, double-blinded, placebo-controlled study | 267 Patients with stable CHF and systolic dysfunction (EF ≤ 40%) (Greece) with mean LVEF of <35% | Intervention group (n = 134): oral colchicine 0.5 mg twice daily (once daily if weight < 60 kg) for 6 months Placebo group (n = 133) | Microtubule inhibitor with anti-inflammatory properties: inhibits NLRP3 inflammasome activation; disruption of leukocyte functions. | 6 months | - Safe use of colchicine; - ↓ hsCRP, IL-6 - No effect on patient functional status, death or hospital stay |
| EXACT-HF study (Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients) (Givertz et al., 2015) | Multi-center, 1:1 randomized, double-blind, placebo-controlled | 253 II–IV NYHA class ischemic and dilated cardiomyopathy HFrEF patients (LVEF ≤ 40%) and elevated serum UA levels (≥ 9.5 mg/dL) (various centers in United States and Canada) | Intervention group (n = 133): Allopurinol was given for 24 weeks starting with 300 mg by mouth once daily for 1 week, and if tolerated, increased to 600 mg daily. Patients unable to tolerate 600 mg were maintained on 300 mg. | Xanthine oxidase inhibitor; besides urate lowering, ↓ oxidative stress and inflammatory mediators. | 6 months | - Failed to improve clinical status, exercise capacity, quality of life, or LVEF at 24 weeks |

ADHF, acute decompensated heart failure; cAMP, cyclic Adenosine Monophosphate; CHF, chronic heart failure; CRP, C-reactive protein; CV, cardiovascular; HFrEF, heart failure with reduced ejection fraction; hsCRP, high sensitive C reactive protein; IL-6, interleukin 6; LVEF, left ventricular ejection fraction; MCP-1, Monocyte chemoattractant Protein-1; NLRP3, NOD-, LRR-and pyrin domain-containing protein 3; NYHA, New York Heart Association; PUFA, polyunsaturated fatty acids; QQ, once a day; SPMs, specialized proresolving mediators; sICAM-1, soluble intercellular adhesion molecule-1; TID, three times daily; TNF-α, Tumor necrosis factor alpha.
randomized clinical trials must assure safety and clinical results (Garcia et al., 1985; Lanier-Smith and Currie, 1990). So, larger to kidney bed (De Matteo and May, 1997; de Matteo and May, renal blood flow mediated by NO and prostaglandins restricted the afferent and efferent arterioles and consequently increasing few studies have demonstrated that glucocorticoids can enhance caused by the stimulation of sodium reabsorption at the level patients with HF because of its related sodium and fluid retention disease (Sun et al., 2021). Glucocorticoid administration is arthritis patients, in order to treat patients with coronary heart is still no sufficient data yet to generalize the prevention of CVD (Webb and Barry, 2020), although it did not provide a benefit in death or HF hospitalization, despite a reduction in inflammatory markers (Deftereos et al., 2014). Thus, the Colchicine in STEMI Patients Study (COVERT-MI), an ongoing confirmative prospective, multicenter, randomized, double-blind trial, is testing whether a short course oral treatment with colchicine versus placebo decreases myocardial injury in patients presenting with STEMI (Bresson et al., 2021), since add-on treatment of coronary artery disease patients already proved to reduce inflammatory biomarkers (Sethuramalingam et al., 2021). The anti-inflammatory effects of methotrexate seem to depend on adenosine receptor stimulation by endogenously generated adenosine (Montesinos et al., 2000). Adenosine is a potent immunomodulatory agent and its receptors activation also induces vasodilation, inhibition of sympathetic neurotransmitter release and induction of ischemic preconditioning, independently of adenosine immunomodulatory effects (Rongen et al., 1997). This could explain why preliminary studies demonstrated cardioprotective effects of raised adenosine concentrations in HF patients (Kitakaze et al., 1998). However, once again, there is still no sufficient data yet to generalize the prevention of incidence of cardiovascular events, demonstrated for rheumatoid arthritis patients, in order to treat patients with coronary heart disease (Sun et al., 2021). Glucocorticoid administration is not recommended routinely in the international guidelines in patients with HF because of its related sodium and fluid retention caused by the stimulation of sodium reabsorption at the level of renal tubules (Ponikowski et al., 2016). On the other hand, few studies have demonstrated that glucocorticoids can enhance natriuresis in HF patients (Liu et al., 2006, 2007; Zhang et al., 2008; Massari et al., 2012), probably by causing vasodilation of the afferent and efferent arterioles and consequently increasing renal blood flow mediated by NO and prostaglandins restricted to kidney bed (De Matteo and May, 1997; de Matteo and May, 1999), as well as by up-regulating ANP synthesis and receptors (Garcia et al., 1985; Lanier-Smith and Currie, 1990). So, larger randomized clinical trials must assure safety and clinical results of COPE-ADHF with enough evidence to promote re-discussion of the main consensus.

Major trials targeting important inflammatory mediators of HF or involving other anti-inflammatory/immunomodulatory strategies in HF are summarized in Tables 1, 2. Most of them were conducted in HFrEF patients, except for the ongoing study with MPO and DHART trials which were specifically designed for HFP EF patients. Contrary to HFrEF, to date, no treatment has been shown to reduce morbidity and mortality in patients with HFP EF (Borlaug, 2020). Although candesartan (Yusuf et al., 2003) and sacubitril/valsartan (Solomon et al., 2020) appear to reduce hospitalizations in patients with LVEF > 40 or 45%, respectively, no randomized clinical trial convincingly reached its primary endpoint. Treating hypervolemia (Adamson et al., 2014) and the mineralocorticoid antagonist spironolactone (Pitt et al., 2014) seemed to produce similar results, with no effect on mortality. On the other hand, nebivolol in SENIORS trial showed promising effects on reduction of cardiovascular mortality but the group of HFP EF considered had LVEF > 35%, including only 15% with a LVEF > 50% (van Veldhuisen et al., 2009). Therefore, the effect of NO-GMPc pathway was also explored but also failed to improve exercise capacity and quality of life (Redfield et al., 2015; Borlaug et al., 2018; Armstrong et al., 2020). Recently, novel evidence emerged strengthening the inflammatory paradigm and reinforcing research for anti-cytokine biological therapy in HFP EF (Paulus and Zile, 2021). For example, higher IL-6 levels were demonstrated to be associated with an increased risk of developing HFP EF (Chia et al., 2021) and circulating levels of TNF-α receptor 2 were shown to be increased in association with the degree of diastolic dysfunction in patients with HFP EF but not HFrEF (Putko et al., 2014). Also, (anti-inflammatory) high density lipoprotein cholesterol/(inflammatory) CRP ratio was shown to be a useful marker for prognostication and correlated with echocardiographic parameters in HFP EF patients (Yano et al., 2021). Moreover, a recent report suggested that the deletion of resolution sensor ALX/FPR2 is associated with the development of diastolic dysfunction related with obesity in mice with HFP EF (Tourki et al., 2020), supporting the concept of non-resolving inflammation in HFP EF (Tourki and Halade, 2021). Besides all this, until now, anti-inflammatory therapies in HFP EF were negative (Murphy et al., 2020), including D-HART2 which failed to improve exercise capacity demonstrated in the pilot study despite lowering CRP and NT-pro-BNP in these patients (Gullestad et al., 2001a; Van Tassell et al., 2018).

CONCLUSION

Since the recognition by Levine et al. (1990) of elevated TNF-α in CHF patients, there has been a growing body of evidence on the association of a myriad of cytokines and chemokines with HFrEF but more recently this has also been demonstrated in the entire clinical spectrum of HF like HFP EF and even in AHF and CS (Mann, 2015). The progression of HF was believed to be due, along with neurohormonal activation, to a sustained inflammatory signaling – chronic para-inflammation – a theory that became collectively known as the “cytokine hypothesis”
Major inflammatory players in HF include TNF-α, IL-1, IL-6, IL-8, IL-10, MPO, iNOS, and CRP, to which experimental and clinical attempts have been directed to target or modulate them. However, the optimal approach seems far to be completed, underscored by the complexity of anti-inflammatory strategies. Although disappointing, negative results do not necessarily argue against the cytokine hypothesis (Dutka et al., 2020). If, in one hand, isolated high intensity anti-TNF-α strategies seem to be rejected, anti-IL-1 and anti-IL-6 therapeutics remain to be explored and individualized. While a new therapeutic strategy such as MPO inhibition is currently being tested, immunomodulators like pentoxifylline, thalidomide, n-3-PUFAs, glucocorticoids or colchicine, already evaluated in preliminary studies, also deserve further larger research. Trials based on serum CRP and UA have underpinned them as biomarkers and probably not as therapeutic targets. In fact, one of the main conclusions we can get from this cytokine hypothesis history is that probably the future will be to tailor the therapeutics according to an inflammatory profile (Van Linthout and Tchópe, 2019) which will require a better knowledge of the players acting on HF immunopathogenesis in order to improve immunomodulatory treatment (Bajaj et al., 2020), or alternatively to promote the resolution of inflammation which remains scarcely studied in human HF (Reina-Couto et al., 2014, 2016; Chirchiu et al., 2019).

AUTHOR CONTRIBUTIONS

MR-C and TS conceived and wrote the manuscript. PP-T, IQ-S, and CS-P wrote the manuscript. TS and AA-T supervised and reviewed the manuscript. All the authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by FEDER funds via COMPETE, Portugal 2020 – Operational Programme for Competitiveness and Internationalization (POCI) (POCI-01-0145-FEDER-032188) and by national funds through the Portuguese Foundation for Science and Technology (FCT) (RIFF-HEART project: PTDC/MEC-CAR/32188/2017). CS-P is a recipient of a Ph.D. fellowship from FCT (UID/BD/150816/2020).

REFERENCES

Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., and Dinarello, C. A. (2020). Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ. Res. 126, 1260–1268. doi: 10.1161/CIRCRESHA.120.315937

Abbate, A., Van Tassell, B. W., Biondi-Zoccai, G., Kontos, M. C., Grizzard, J. D., Spillman, D. W., et al. (2013). Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am. J. Cardiol. 111, 1394–1400. doi: 10.1016/j.amjcard.2013.01.287

Adamo, L., Rocha-Resende, C., Prabhu, S. D., and Mann, D. L. (2020). Reappraising the role of inflammation in heart failure. Nat. Rev. Cardiol. 17, 269–285. doi: 10.1038/s41569-019-0315-x

Adamson, P. B., Abraham, W. T., Bourge, R. C., Costanzo, M. R., Hasan, A., Yadav, C., et al. (2014). Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ. Heart Fail. 7, 935–944. doi: 10.1161/CIRCHEARTFAILURE.113.001229

Ali, M., Pulli, B., Courties, G., Tricot, B., Sebas, M., Iwamoto, Y., et al. (2016). Myeloperoxidase inhibition improves ventricular function and remodeling after experimental myocardial infarction. JACC Basic Transl. Sci. 1, 633–643. doi: 10.1016/j.jacbts.2016.09.004

Altara, R., Ghali, R., Mallat, Z., Cataliotti, A., Booz, G. W., and Zouein, F. A. (2018). Conflicting vascular and metabolic impact of the IL-33/sST2 axis. Cardiovasc. Res. 114, 1578–1594. doi: 10.1093/cvr/cvy166

Anand, I. S., Latini, R., Florea, V. G., Kukowski, M. A., Rector, T., Masson, S., et al. (2005). C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112, 1428–1434. doi: 10.1161/CIRCULATIONAHA.104.508465

Anker, S. D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., et al. (2003). Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107, 1991–1997. doi: 10.1161/01.CIR.0000065637.10517.A0

Apostolakis, S., Vogiatzi, K., Amanatidou, V., and Spandiidis, D. A. (2009). Interleukin 8 and cardiovascular disease. Cardiovasc. Res. 84, 353–360. doi: 10.1093/cvr/cvp241

Armstrong, P. W., Lam, C. S. P., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., O’Connor, C. M., et al. (2020). Effect of Vericiguat vs Placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial. JAMA 324, 1512–1521. doi: 10.1001/jama.2020.15922

Askari, A. T., Brennan, M. L., Zhou, X., Drinko, J., Morehead, A., Thomas, J. D., et al. (2003). Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J. Exp. Med. 197, 615–624. doi: 10.1084/jem.20021426

Aukrust, P., Yndestad, A., Damas, J. K., Ueland, T., Oie, E., and Gullestad, L. (2007). Potential mechanisms of benefit with thalidomide in chronic heart failure. Am. J. Cardiovasc. Drugs 7, 127–134. doi: 10.2165/00129784-200707020-00004

Bailey, A., Pope, T. W., Moore, S. A., and Campbell, C. L. (2007). The tragedy of TRIUMPH for nitric oxide synthesis inhibition in cardiogenic shock: where do we go from here? Am. J. Cardiovasc. Drugs 7, 337–345. doi: 10.2165/00129784-200707050-00003

Bajaj, N. S., Gupta, K., Gharpure, N., Pate, M., Chopra, L., Kalra, R., et al. (2020). Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature. ESC Heart Fail 7, 1319–1330. doi: 10.1002/ehf2.12681

Bartekova, M., Radosinska, J., Jelemský, M., and Dhallá, N. S. (2018). Role of cytokines and inflammation in heart function during health and disease. Heart Fail Rev 23, 733–758. doi: 10.1007/s10741-018-9716-x

Basuik, S. S., Rifai, N., and Ridker, P. M. (2004). High-sensitivity C-reactive protein: clinical importance. Curr. Probl. Cardiol. 29, 439–493

Berry, M. F., Woo, Y. J., Piroli, T. J., Bish, L. T., Moise, M. A., Burdick, J. W., et al. (2004). Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. J. Heart Lung Transplant. 23, 1061–1068. doi: 10.1016/j.healun.2004.06.021

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 380, 11–22. doi: 10.1056/NEJMoai1812792

Bian, R. T., Wang, Z. T., and Li, W. Y. (2021). Immunoadsorption treatment for dilated cardiomyopathy: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 100:e26475. doi: 10.1097/MD.0000000000026475
without cardiacogenic shock. *Clin. Res. Cardiol.* 97, 298–305. doi: 10.1007/s00392-007-0626-5

Delftereos, S., Giannopoulos, G., Panagopoulos, V., Bouras, G., Raisakis, K., Kossyvakis, C., et al. (2014). Anti-inflammatory treatment with colchicine in stable chronic heart failure: A prospective, randomized study. *JACC Heart Fail.* 2, 131–137. doi: 10.1016/j.jchf.2013.11.006

Demyanets, S., Kaun, C., Rentz, R., Krychtiuk, K. A., Rauscher, S., Paffenberger, S., et al. (2013). Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. *J. Mol. Cell. Cardiol.* 60, 16–26. doi: 10.1016/j.yjmcc.2013.03.020

Demyanets, S., Konya, V., Kastl, S. P., Kaun, C., Rauscher, S., Niessner, A., et al. (2011). Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. *Artiosciences. Thromb. Vasc. Biol.* 31, 2080–2089. doi: 10.1161/ATVBAHA.111.231431

Desai, A. S., and Stevenson, L. W. (2012). Rehospitalization for heart failure: predict or prevent? *Circulation* 126, 501–506. doi: 10.1161/CIRCULATIONAHA.112.125435

Deswal, A., Bozkurt, B., Seta, Y., Parilii-Eiswirth, S., Hayes, F. A., Blosh, C., et al. (1999). Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. *Circulation* 99, 3224–3226. doi: 10.1161/01.CIR.99.23.3224

Dhingra, S., Bagchi, A. K., Ludke, A. L., Sharma, A. K., and Singal, P. K. (2011). AkT regulates IL-10 mediated suppression of TNFalpha-induced cardiomyocyte apoptosis by upregulating Stat3 phosphorylation. *PLoS One* 6:e25509. doi: 10.1371/journal.pone.0025509

Dhingra, S., Sharma, A. K., Arora, R. C., Slezak, J., and Singal, P. K. (2009). IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis. *Cardiovasc. Res.* 82, 59–66. doi: 10.1093/ctr/cyp040

Dinarello, C. A., Novick, D., Luddke, A. L., and Kaplanski, G. (2013). Interleukin-18 and Finkel, M. S., Oddis, C. V., Jacob, T. D., Watkins, S. C., Hatliger, B. G., and Simmons, R. L. (1992). Negative inotropic effects of cytokines on the heart mediated by nitric oxide. *Science* 257, 387–389. doi: 10.1126/science.1631560 Frangiogniannis, N. G. (2015). Interleukin-1 in cardiac injury, repair, and remodeling: pathophysiological and translational concepts. *Discoveries (Craiova)* 3:e11. doi: 10.15190/d.2015.33

Gabay, C. (2006). Interleukin-6 and chronic inflammation. *Arthritis. Res. Ther.* 8:33. doi: 10.1186/ar1917

Gabay, C., Fautrel, B., Rech, J., Sperti, F., Feist, E., Kottet, L., et al. (2018). Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of takedinig alfa (IL-18BBP) in adult-onset Still’s disease. *Ann. Rheum. Dis.* 77, 840–847. doi: 10.1136/annrheumdis-2017-212608

Gan, L. M., Lagerstrom-Fermer, M., Ericsson, H., Nelander, K., Lindstedt, E. L., Michaelsson, E., et al. (2019). Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers. *Br. J. Clin. Pharmacol.* 85, 762–770. doi: 10.1111/bcp.13855

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., et al. (1985). Glucoc- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. *Biochem. Biophys. Res. Commun.* 131, 806–814. doi: 10.1016/0006-2915(85)91131-7

Geppert, A., Dorninger, A., Delle-Karth, G., Zorn, G., Heinz, G., and Huber, K. (2006). Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. *Crit. Care Med.* 34, 2035–2042. doi: 10.1097/01.CCM.0000228919.33620.D9

Ghali, R., Alivisatos, M., Louch, W. E., Cataliotti, A., Mallat, Z., Kaplan, A., et al. (2018). IL-33 (Interleukin 33)/ST2 axis in hypertension and heart failure. *Hypertension* 72, 818–828. doi: 10.1154/HYPERTENSIONAHA.111.11157

Givertz, M. M., Anstrom, K. J., Redfield, M. M., Deswal, A., Haddad, H., Butler, J., et al. (2015). Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: The xanthine oxidase inhibition for hyperuricemic Heart Failure Patients (EXACT-HF) study. *Circulation* 131, 1763–1771. doi: 10.1161/CIRCULATIONAHA.114.014536

Glezeva, N., and Baugh, J. A. (2014). Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. *Heart Fail. Rev.* 19, 681–694. doi: 10.1007/s10741-013-9405-0

Gong, K., Zhang, Z., Sun, X., Zhang, X., Li, A., Yan, J., et al. (2006). The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. *Am. Heart J.* 151, 62–68. doi: 10.1016/j.ahj.2005.02.040

Gotsman, I., Keren, A., Lotan, C., and Zwas, D. R. (2012). Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. *J. Card Fail.* 18, 694–701. doi: 10.1016/j.cardfail.2012.06.528

Griselli, M., Herbert, J., Hutchinson, W. L., Taylor, K. M., Sohail, M., Krauss, T., et al. (1999). C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. *J. Exp. Med.* 190, 1733–1740. doi: 10.1084/jem.190.12.1733

Gullestad, L., Ueland, T., Brunsvig, A., Kjekshus, J., Simonsen, S., Froland, S. S., et al. (2011). Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. *Arterioscler. Thromb. Vasc. Biol.* 31, 2080–2089. doi: 10.1161/ATVBAHA.111.231431
Kjekshus, J., Apetrei, E., Barrios, V., Bohl, M., Cleland, J. G., Cornel, J. H., et al. (2007). Rosuvastatin in older patients with systolic heart failure. *N. Engl. J. Med.* 357, 2248–2261. doi: 10.1056/NEJMoa0706201

Kleveland, O., Kunzt, G., Bratlie, M., Ueland, T., Broch, K., Holte, E., et al. (2016). Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. *Eur. Heart J.* 37, 2406–2413. doi: 10.1093/eurheartj/ehw171

Kobayashi, H., Kobayashi, Y., Iones, T. J., Yoneyma, K., Nakajima, Y., and Takei, M. (2014). Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging. *J. Rheumatol.* 41, 1916–1921. doi: 10.3899/jrheum.131540

Koenig, W., Khuseynova, N., Baumert, J., Thorand, B., Loewel, H., Chambless, L., et al. (2006). Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. *Arterioscler. Thromb. Vasc. Biol.* 26, 2745–2751. doi: 10.1161/01.ATV.0000248966.62495.73

Kohsaka, S., Menon, V., Lowe, A. M., Lange, M., Dzavik, V., Sleeper, L. A., et al. (2007). Elevated binding of atrial natriuretic peptide to endothelial cells. *Eur. J. Pharmacol.*

Krum, H., Ashton, E., Reid, C., Kalff, V., Rogers, J., Amarena, J., et al. (2006). Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. *Arterioscler. Thromb. Vasc. Biol.* 26, 2745–2751. doi: 10.1161/01.ATV.0000248966.62495.73

Kohsaka, S., Menon, V., Lowe, A. M., Lange, M., Dzavik, V., Sleeper, L. A., et al. (2005). Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiac shock. *Arch. Intern. Med.* 165, 1643–1650. doi: 10.1001/archinte.165.14.1643

Kozuharov, N., Guede, A., Flores, D., Maeder, M. T., Walter, J., Shrestha, S., et al. (2019). Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: The GALACTIC randomized clinical trial. *JAMA Cardiol.* 32, 2292–2302. doi: 10.1001/jama.2019.18598

Krishnamurthy, P., Rajasingh, J., Lambers, E., Qin, G., Losordo, D. W., and Kishore, R. (2009). IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of NF-kB. *Circ. Res.* 105, 109–119. doi: 10.1161/CIRCRESAHA.116.302317

Mann, D. L., McMurray, J. J., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., et al. (2004). Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation* 109, 1594–1603. doi: 10.1161/01.CIR.0000124490.27666.B2

Manzano-Fernandez, S., Mueller, T., Pascual-Fidal, D., Truong, Q. A., and Januzzi, J. L. (2011). Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. *Am. J. Cardiol.* 107, 259–267. doi: 10.1016/j.amjcard.2010.09.011

Massari, F., Mastropasqua, F., Iacoviello, M., Nuzzolese, V., Torres, D., and Parrinello, G. (2012). The glucocorticoid in acute decompensated heart failure: De Jekyll or Mr Hyde? *Am. J. Emerg. Med.* 30:517. doi: 10.1016/j.ajem.2011.01.023

Matteck, S., Brunner, P., Hahnel, B., Kunze, R., Vogt, B., and Sherriff, A. (2019). PentraSorb C-reactive protein: characterization of the selective c-reactive protein adsorber resin. *Ther. Apher. Dial.* 23, 474–481. doi: 10.1111/1744-9987.12796

Matilla, P., Majuri, M. L., Mattila, P. S., and Renkonen, R. (1992). TNF alpha-induced expression of endothelial adhesion molecules, ICAM-1 and VCAM-1, is linked to protein kinase C activation. *Scand. J. Immunol.* 36, 159–165. doi: 10.1111/j.1365-3083.1992.tb03087.x

McCarthy, C. P., and Januzzi, J. L. Jr. (2018). Soluble ST2 in heart failure. *Heart Fail. Clin.* 14, 41–48. doi: 10.1016/j.hfc.2017.08.005

Mckie, E. A., Reid, J. L., Mistry, P. C., DeWall, S. L., Abberley, L., Ambery, P. D., et al. (2016). A Study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. *PLoS One* 11(e0150018). doi: 10.1371/journal.pone.0150018

Mebazaa, A., Tolppanen, H., Mueller, C., Lassus, J., DiSomma, S., Baksyte, G., et al. (2019). Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. *Intensive Care Med.* 45, 147–163. doi: 10.1007/s00134-015-4041-5

Mentz, R. J., and O'Connor, C. M. (2016). Pathophysiology and clinical evaluation of acute heart failure. *Nat. Rev. Cardiol.* 13, 28–35. doi: 10.1038/nrcardi.2015.134

Michelucci, A., Riccardi, G., Soffi, F., Gori, A. M., Pirlo, F., Pieragnoli, P., et al. (2007). Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy. *J. Card Fail.* 13, 207–210. doi: 10.1016/j.cardfail.2006.11.013

Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M., and Shima, M. (2012). IL-6/IL-6 receptor system and its role in physiological and pathological conditions. *Clin. Sci. (Lond.*) 122, 143–159. doi: 10.1042/CS20110340

Moe, G. W., Marin-Garcia, J., Konig, A., Goldenthal, M., Lu, X., and Feng, Q. (2004). In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. *Circ. Res.* 94, 1598–1607. doi: 10.1161/01.RES.0000124490.27666.B2
Montesinos, M. C., Yap, J. S., Desai, A., Posadas, I., McCrory, C. T., and Cronestein, B. N. (2000). Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. *Arthritis Rheum.* 43, 656–663. doi: 10.1002/art.12513–656-AD-NR23+3.0.CO;2-H

Moreira, D. M., Vieira, J. L., and Gottschall, C. A. (2009). The effects of METHotrexate therapy on the physical capacity of patients with ischemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial). *J. Card Fail.* 15, 828–834. doi: 10.1016/j.cardfail.2009.06.039

Murphy, S. P., Kakkar, R., McCarthy, C. P., and Januzzi, J. L. Jr. (2020). Inflammation in heart failure: JACC state-of-the-art review. *J. Am. Coll. Cardiol.* 75, 1324–1340. doi: 10.1016/j.jacc.2020.01.014

Ndrepepa, G. (2019). Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease. *Clin. Chim. Acta* 493, 36–51. doi: 10.1016/j.cca.2019.02.022

Nelander, K., Lagerstrom-Fermier, M., Amilon, C., Michaelsson, E., Heijeer, M., Kjaer, M., et al. (2021). Early clinical experience with AZD4831, a novel myeloperoxidase inhibitor, developed for patients with heart failure with preserved ejection fraction. *Clin. Transl. Sci.* 14, 812–819. doi: 10.1111/cts.12859

Nesser, J., Nesser, B., Golebiowska-Wiatrak, R., Palka, I., Gackowski, A., Kitlinski, Ng, L. L., Pathik, B., Loke, I. W., Squire, I. B., and Davies, J. E. (2006). Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. *PloS One* 9:e99495. doi: 10.1371/journal.pone.0099495

Ramani, G. V., Uber, P. A., and Mehra, M. R. (2010). Chronic heart failure: contemporary diagnosis and management. *Mayo Clin. Proc.* 85, 180–195. doi: 10.4065/mcp.2009.0494

Rathi, S. S., Xu, Y. J., and Dhalla, N. S. (2002). Mechanism of cardioprotective action of TNF-alpha in the isolated rat heart. *Exp. Clin. Cardiol.* 7, 146–150.

Reina-Couto, M., Vale, L., Carvalho, J., Bettencourt, P., Albino-Teixeira, A., Afonso, J., et al. (2014). Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. *Eur. J. Heart Fail.* 16, 68–75. doi: 10.1093/eurhj/hft125

O’Brien, L. C., Mezzaroma, E., Van Tassell, B. W., Marchetti, C., Carbone, S., Abbate, A., et al. (2014). Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. *Mol. Med.* 20, 221–229. doi: 10.2119/molmed.2014.00034

Pacher, P., Beckman, J. S., and Liaudet, L. (2007). Nitric oxide and peroxynitrite in inflammation in heart failure: JACC state-of-the-art review. *Clin. Res. Cardiol.* 101, 375–384. doi: 10.1007/s00392-011-0403-3

Pugliese, N. R., Fabiani, I., Conte, L., Nesti, L., Masi, N., Natali, A., et al. (2020). Persistent congestion, renal dysfunction and inflammatory cytokines in acute heart failure: a prognosis study. *J. Cardiovasc. Med. (Hagerstown)* 21, 494–502. doi: 10.10245/JCM.0000000000000974

Putko, B. N., Wang, Z., Lo, J., Anderson, T., Becher, H., Dyck, J. R., et al. (2014). Persistent inflammation with elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. *Circulation* 108, 2292–2297. doi: 10.1161/CIRCULATIONAHA.112.1133731

Pollheimer, J., Bodin, J., Sundnes, O., Edelmann, R. J., Skanland, S. S., Sponheim, J., et al. (2013). Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells. *Arterioscler. Thromb. Vasc. Biol.* 33, e17–e55. doi: 10.1161/ATVBAHA.112.253427

 Ponkowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur. J. Heart Fail.* 18, 891–975. doi: 10.1002/ejhf.592

Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., et al. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N. Engl. J. Med.* 377, 1119–1131. doi: 10.1056/NEJMOa1707914

Ridker, P. M., Buring, J. E., Cook, N. R., and Rifai, N. (2003). C-reactive protein, lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: a marker of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. *Circulation* 108, 2292–2297. doi: 10.1161/CIRCULATIONAHA.112.1133731

Ridker, P. M., and Group, J. S. (2003). Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. *Circulation* 108, 2292–2297. doi: 10.1161/01.CIR.0000100688.17280.E6

Reina-Couto et al. Inflammation in Human Heart Failure
Sliwa, K., Woodiwiss, A., Candy, G., Badenhorst, D., Norton, G., Sheriff, A., Kayser, S., Brunner, P., and Vogt, B. (2021). C-reactive protein triggers cell death in ischemic cells. Front. Immunol. 12, 650340. doi: 10.3389/fimmu.2021.650340

Shpektor, A. (2010). Cardiogenic shock: the role of inflammation. Acute Card Care 12, 115–118. doi: 10.1016/S1748-2941(10)523705

Sivasubramanian, N., Coker, M. L., Kurrelmeyer, K. M., MacLellan, W. R., DeMayo, F. J., Spinalle, F. G., et al. (2001). Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 104, 826–831. doi: 10.1161/01.01CIRC.3010391534

Sliwa, K., Woodiwiss, A., Candy, G., Badenhorst, D., Libhaver, C., Norton, G., et al. (2002). Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompenesed congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am. J. Cardiol. 90, 1118–1122. doi: 10.1016/S0002-9149(02)02779-0

Sliwa, K., Woodiwiss, A., Kone, V. N., Candy, G., Badenhorst, D., Norton, G., et al. (2004). Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 109, 750–755. doi: 10.1161/01.CIR.0000112568.48837.60

Solomon, S. D., Vaduganathan, M., Cagbett, B. L., Packer, M., Zile, M., Swedberg, K., et al. (2020). Sacubitril/Valsartan across the spectrum of ejection fraction in heart failure. Circulation 141, 352–361. doi: 10.1161/CIRCULATIONAHA.119.045886

Song, Y., Li, F., Xu, Y., Liu, Y., Wang, Y., Han, X., et al. (2020). Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction. Int. J. Cardiol. 304, 95–100. doi: 10.1016/j.ijcard.2020.01.039

Soskic, S. S., Dobutovic, B. D., Sadar, E. M., Obradovic, M. M., Nikolic, D. M., Djordjevic, J. D., et al. (2011). Regulation of Inducible Nitric Oxide Synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure. Open Cardiovasc. Med. J. 5, 153–163. doi: 10.2174/17494904105010153

Sousa, T., Reina-Couto, M., and Gomes, P. (2019). “Role of Oxidative Stress in the Pathophysiology of Arterial Hypertension and Heart Failure” in Oxidative Stress in Heart Diseases, eds S. Chakraborti, N. S. Dhalla, M. K. Ganguly, and M. Dikshit (Singapore: Springer), 509–537.

Speranza, L., Franceschelli, S., Riccioni, G., Di Nicola, M., Ruggeri, B., Gallina, S., et al. (2012). BNP and iNOS in decompensated chronic heart failure: a linear correlation. Front. Biosci. (Elite Ed) 4, 1255–1262. doi: 10.2741/G56

Spodick, D. H. (2003). Acute cardiac tamponade. N. Engl. J. Med. 349, 684–690. doi: 10.1056/NEJMra022643

Srivastava, P. K., Hsu, J. J., Ziaean, B., and Fonarow, G. C. (2020). Heart failure with mid-range ejection fraction. Curr. Heart Fail. Rep. 17, 1–8. doi: 10.1007/s11897-019-00451-0

Stull, L. B., Leppo, M. K., Szewda, L., Gao, W. D., and Marban, E. (2004). Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ. Res. 95, 1005–1011. doi: 10.1161/01.RES.0000148635.73331.c5

Suematsu, N., Tsutsui, H., Wen, J., Kang, D., Ikeuchi, M., Ide, T., et al. (2003). Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107, 1418–1423. doi: 10.1161/01.CIR.0000055318.09997.1f

Sun, K. J., Liu, L. L., Hu, J. H., Chen, Y. Y., and Xu, D. Y. (2021). Methrotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis. Medicine (Baltimore) 100:e24357. doi: 10.1097/MD.00000000000024357

Sun, M., Chen, M., Dawood, F., Zurawska, U., Li, J. Y., Parker, T., et al. (2007). Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Anatol. J. Cardiol. 21, 305–313. doi: 10.14744/AnatolCardiol.2019.946414

Segiet, O. A., Romuk, E., Nowalany-Kozielska, E., Wojnicz, R., and Wojnicz, R. (2019b). The concentration of interleukin-33 in heart failure with reduced ejection fraction. Anatol. J. Cardiol. 19, 287–299. doi: 10.14744/AnatolCardiol.2019.32 748

Segiet, O. A., Romuk, E., Nowalany-Kozielska, E., Wojciechowska, C., Piecuch, A., and Wojnicz, R. (2019b). The concentration of interleukin-33 in heart failure with reduced ejection fraction. Anatol. J. Cardiol. 21, 305–313. doi: 10.14744/AnatolCardiol.2019.64614

Sangad, S., Hakuno, D., Higgins, L. J., Schreiter, E. R., McKenney, A. N., and Lee, R. T. (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538–1549. doi: 10.1172/JCI30634

Sanchez, I., Santana, S., Escobar, C., Santiago, J. L., Gonzalez, A., Ribas, N., et al. (2014). Clinical implications of different biomarkers in elderly patients with heart failure. Biomark. Med. 8, 335–341. doi: 10.2217/bmm.14.24

Sanders, D. B., Larson, D. F., Hunter, K., Gorman, M., and Yang, B. (2001). Comparison of tumor necrosis factor-alpha effect on the expression of iNOS in macrophage and cardiac myocytes. Perfusion 16, 67–74. doi: 10.1076/perf.16.5.67.5701

Scirica, B. M., Morrow, D. A., Cannon, C. P., Ray, K. K., Sabatine, M. S., Jarolim, R. T. (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538–1549. doi: 10.1172/JCI30634

Sanchez, I., Santana, S., Escobar, C., Santiago, J. L., Gonzalez, A., Ribas, N., et al. (2014). Clinical implications of different biomarkers in elderly patients with heart failure. Biomark. Med. 8, 335–341. doi: 10.2217/bmm.14.24

Sanders, D. B., Larson, D. F., Hunter, K., Gorman, M., and Yang, B. (2001). Comparison of tumor necrosis factor-alpha effect on the expression of iNOS in macrophage and cardiac myocytes. Perfusion 16, 67–74. doi: 10.1076/perf.16.5.67.5701

Scirica, B. M., Morrow, D. A., Cannon, C. P., Ray, K. K., Sabatine, M. S., Jarolim, R. T. (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538–1549. doi: 10.1172/JCI30634
Tavazzi, L., Maggioni, A. P., Marchioli, R., Barlera, S., Franzosi, M. G., Latini, R., et al. (2008a). Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1223–1230. doi: 10.1016/S0140-6736(08)61239-8

Taylor, A. L., Ziesche, S., Vancy, C., Carson, P., D’Agostino, R. Jr., Ferdinand, K., et al. (2004). Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351, 2091–2097. doi: 10.1056/NEJMoa042934

Tentolouris, C., Tousoulis, D., Antoniades, C., Bosinakou, E., Kotsopoulou, M., Trikas, A., et al. (2004). Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Int. J. Cardiol. 94, 301–305. doi: 10.1016/j.ijcard.2003.08.002

Thiele, J. R., Zeller, J., Bannasch, H., Stark, G. B., Peter, K., and Eisenhardt, S. U. (2015). Targeting C-Reactive protein in inflammatory disease by preventing conformational changes. Mediators Inflamm. 2015:372432. doi: 10.1155/2015/372432

Tomasoni, D., Adamo, M., Lombardi, C. M., and Metra, M. (2019). Highlights in heart failure. ESC Heart Fail. 6, 1105–1127. doi: 10.1002/ehf2.12555

Tourki, B., and Halade, G. V. (2021). Heart failure syndrome with preserved ejection fraction is a metabolic cluster of non-resolving inflammation in obesity. Front. Cardiovasc. Med. 8, 695952. doi: 10.3389/fcm.cv.2021.695952

Tourki, B., Kain, V., Shaikh, S. R., Leroy, X., Serhan, C. N., and Halade, G. V. (2020). Deficit of resolution receptor magnifies inflammatory leukocyte directed cardiorenal and endothelial dysfunction with signs of cardiomyopathy of obesity. FASEB J. 34, 10560–10573. doi: 10.1096/fj.202000495RR

Tischendorf, C., Ammirati, E., Bozkurt, B., Cafiero, A. L. P., Cooper, L. T., Felix, S. B., et al. (2021). Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat. Rev. Cardiol. 18, 169–193. doi: 10.1038/s41569-020-00435-x

Tsutamoto, T., Hisanaga, T., Wada, A., Maeda, K., Ohnishi, M., Fukai, D., et al. (1998). Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol. 31, 391–398. doi: 10.1016/S0735-1097(97)00494-4

Urschel, K., and Cicha, I. (2015). TNF-α in the cardiovascular system: from physiologic to therapy. Int. J. Interferon Cytokine Res. 7, 9–25. doi: 10.2147/IJICMR.S64894

danke, J., Mortensen, S. A., et al. (1998). Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J. Mol. Cell. Cardiol. 30, 1215–1223. doi: 10.1006/jmcc.1998.0686

Verma, S. K., Krishnamurthy, P., Barefield, D., Singh, N., Gupta, R., Lambers, E., et al. (2012). Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-kappaB. Circulation 126, 418–429. doi: 10.1161/CIRCULATIONAHA.112.112185

Villegas, S., Villarreal, F. J., and Dillmann, W. H. (2000). Leukemia inhibitory factor and interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes. Basic Res. Cardiol. 95, 47–54. doi: 10.1007/s00395-000-0007

Virzi, G. M., Breglia, A., Brocca, A., de Cal, M., Bolin, C., Vescovo, G., et al. (2018). Levels of proinflammatory cytokines, oxidative stress, and tissue damage markers in patients with acute heart failure with and without cardiorenal syndrome type 1. Cardiovasc. Med. 8, 321–331. doi: 10.1159/000492602

Wang, M., Markel, T. A., and Meldrum, D. R. (2008). Interleukin 18 in the heart. Shock 30, 3–10. doi: 10.1097/SHK.0b013e318160f125

Webb, C. A., and Barry, A. R. (2020). Colchicine for secondary cardiovascular prevention: A systematic review. Pharmacotherapy 40, 575–583. doi: 10.1002/ phar.2401

White, M., Ducharme, A., Ibrahim, R., Whittom, L., Lavoie, J., Guertin, M. C., et al. (2006). Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term isotropic support. Clin. Sci. (Lond) 110, 483–489. doi: 10.1042/CS20050317

Wlodzek, E., Kirkpatrick, R. B., Andrews, S., Noble, R., Schroyer, R., Scott, J., et al. (2021). A pilot study evaluating GSX1070806 inhibition of interleukin-18 in renal transplant delayed graft function. PLoS One 16:e0247972. doi: 10.1371/journal.pone.0247972

Xiang, N., Liao, H., Zhai, Z., and Gong, J. (2021). Expression and significance of inflammatory reactions mediated by the IL-33/ST2 signaling pathway in the serum of heart failure patients. Am. J. Transl. Res. 13, 8427–8452.

Yang, Y., Lv, J., Jiang, S., Ma, Z., Wang, D., Hu, W., et al. (2016). The emerging role of Toll-like receptor 4 in myocardial inflammation. Cell. Death Dis. 7:e2234. doi: 10.1038/cddis.2016.140

Yano, M., Nishino, M., Ukita, K., Kawamura, A., Nakamura, H., Matsuhiro, Y., et al. (2021). High density lipoprotein cholesterol / C reactive protein ratio in heart failure with preserved ejection fraction. ESC Heart Fail. 8, 2791–2801. doi: 10.1002/ehf2.13350

Yasojima, K., Schwab, C., McGeer, E. G., and McGeer, P. L. (2001). Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol. 158, 1039–1051. doi: 10.1016/S0002-9440(10)64051-5

Yndestad, A., Damas, J. K., Oie, E., Ueland, T., Gullestad, L., and Aukrust, P. (2006). Targeting C-Reactive protein in inflammatory disease by preventing conformational changes. Mediators Inflamm. 2015:372432. doi: 10.1155/2015/372432

Yokoe, I., Kobayashi, H., Kobayashi, Y., Giles, J. T., Yoneyama, K., Kitamura, N., et al. (2018). Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand. J. Rheumatol. 47, 364–370. doi: 10.1080/03009742.2017.1418424
Yokoyama, T., Vaca, L., Rossen, R. D., Durante, W., Hazarika, P., and Mann, D. L. (1993). Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J. Clin. Invest. 92, 2303–2312.

Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., et al. (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362, 777–781. doi: 10.1016/S0140-6736(03)14285-7

Zell, R., Geck, P., Werdan, K., and Boekstegers, P. (1997). TNF-alpha and IL-1 alpha inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Mol. Cell. Biochem. 177, 61–67. doi: 10.1023/a:1006896832582

Zhang, H., Liu, C., Ji, Z., Liu, G., Zhao, Q., Ao, Y. G., et al. (2008). Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int. Heart J. 49, 587–595. doi: 10.1536/ihj.49.587.

Zhang, H. F., Xie, S. L., Chen, Y. X., Mai, J. T., Wang, J. F., Zhu, W. L., et al. (2012). Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress. J. Transl. Med. 10:120. doi: 10.1186/1479-5876-10-120

Zhang, M., Xu, Y. J., Mengi, S. A., Arneja, A. S., and Dhall, N. S. (2004). Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp. Clin. Cardiol. 9, 103–111.

Zhang, P., Xu, X., Hu, X., van Deel, Zhu, G., and Chen, Y. (2007). Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ. Res. 100, 1089–1098. doi: 10.1161/01.RES.0000264081.78659.45

Zimmermann, O., Bienek-Ziolkowski, M., Wolf, B., Vetter, M., Baur, R., Mailander, V., et al. (2009). Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein? Basic Res. Cardiol. 104, 591–599. doi: 10.1007/s00395-009-0026-2

Zimnet, J. M., and Hare, J. M. (2006). Nitroso-redox interactions in the cardiovascular system. Circulation 114, 1531–1544. doi: 10.1161/01.CIR.105.605519

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Reina-Couto, Pereira-Terra, Quelhas-Santos, Silva-Pereira, Albino-Teixeira and Sousa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.